Document:

EX-10.9

 Exhibit 10.9 

CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE VIVIDION THERAPEUTICS, INC. HAS DETERMINED THAT
IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT VIVIDION THERAPEUTICS, INC. TREATS AS PRIVATE OR CONFIDENTIAL. 
 LICENSE AGREEMENT

 by and between 

THE SCRIPPS RESEARCH INSTITUTE, 

a California nonprofit 

public benefit corporation 

and 
 Vividion
Therapeutics, Inc., 
 a Delaware corporation 
  

 LICENSE AGREEMENT 

This License Agreement is entered into and made effective as of this 6th day of
January, 2016 (the “Effective Date”), by and between THE SCRIPPS RESEARCH INSTITUTE, a California nonprofit public benefit corporation (“TSRI”), and VIVIDION THERAPEUTICS, INC., a Delaware corporation
(“Licensee”), each located at the respective address set forth in Section 14.16 below, with respect to the facts set forth below. 

RECITALS 
 A. TSRI
is engaged in fundamental scientific biomedical and biochemical research including research relating to compounds for the prevention, diagnosis and/or treatment of diseases, as more particularly described herein. 

B. Licensee is engaged in research and development of molecules for the prevention, diagnosis and/or treatment of diseases. 

C. TSRI has disclosed to Licensee certain technology and TSRI has the right to grant a license to the technology, subject to certain rights of
the U.S. Government resulting from the receipt by TSRI of certain funding from the U.S. Government. 
 D. TSRI desires to grant to Licensee,
and Licensee wishes to acquire from TSRI, a worldwide right and license to certain patent rights of TSRI, subject to the terms and conditions set forth herein. 

E. TSRI and Licensee are parties to that certain Research Funding and Option Agreement dated Sept. 15, 2014 (the “RFOA”),
pursuant to which: (i) Licensee is providing certain funding to TSRI to support research related to chemical proteomics in the laboratory of Dr. Benjamin Cravatt; and (ii) the parties have agreed that Licensee has an exclusive option
to license all Patent Rights and Technology (as such terms are defined in the RFOA) arising under the RFOA on the terms and conditions set forth in this Agreement. In the event of a conflict between the terms of this Agreement and the terms of the
RFOA, the terms of this Agreement shall control. 
 AGREEMENT 

NOW, THEREFORE, in consideration of the mutual covenants and conditions set forth herein, TSRI and Licensee hereby agree as follows: 

1. Definitions. Capitalized terms shall have the meaning set forth herein. 

1.1 Affiliate. The term “Affiliate” shall mean any entity which directly or indirectly controls, or is controlled by
Licensee. The term “control” as used herein means (a) in the case of corporate entities, direct or indirect ownership of at least fifty percent (50%) of the stock or shares entitled to vote for the election of directors; or
(b) in the case of non-corporate entities, direct or indirect ownership of at least fifty percent (50%) of the equity interest with the power to direct the management and policies of such non-corporate entities. Unless otherwise specified, the term Licensee includes Affiliates. 

  
 1 

 1.2 Applicable Royalty Rate, or ARR. The term “Applicable Royalty Rate” or
“ARR” shall mean, with respect to a Product, the royalty rate applicable to Net Sales of such Product specified in Section 3.5 (prior to giving effect to any adjustments that may be applicable under Section 3.6 and/or
Section 3.7). 
 1.3 Challenge. Licensee will be deemed to have made a “Challenge” of the Licensed Patent Rights if
Licensee or its Affiliate or Sublicensee: (a) institutes or maintains, or causes its counsel to institute or maintain on Licensee’s or such Affiliate’s or Sublicensee’s behalf, any interference, opposition, re-examination, post-grant review or similar proceeding with respect to any Licensed Patent Right with the U.S. Patent and Trademark Office or any foreign patent office; or (b) makes any filing or institutes or
maintains any legal proceeding, or causes its counsel to make any filing or institute or maintain any legal proceeding on Licensee’s or such Affiliate’s or Sublicensee’s behalf, with a court or other governmental body (including,
without limitation, the U.S. Patent and Trademark Office or any foreign patent office) in which one or more claims or allegations challenges the validity or enforceability of any Licensed Patent Right; provided, however, that, any such action
described in subsection (a) and/or (b) by a Sublicensee shall not be deemed to be a Challenge if Licensee, within [***] days of the filing of such action, procures and causes to be filed a dismissal with prejudice of such action, and
terminates the agreement granting such Sublicensee a sublicense with respect to the Licensed Patent Rights in accordance with the terms of such agreement and, following such termination, such Challenging party is no longer a Sublicensee. 

1.4 Confidential Information. The term “Confidential Information” shall mean any and all proprietary or confidential
information of TSRI or Licensee that such party (the “Disclosing Party”) discloses to the other party (the “Receiving Party”) at any time and from time to time during the term of this Agreement. Information shall
not be considered confidential to the extent that the Receiving Party can establish by competent proof that it: 
 (a) Is publicly
disclosed through no fault of the Receiving Party, either before or after it becomes known to the Receiving Party; 
 (b) Was known to the
Receiving Party prior to the date of this Agreement, which knowledge was acquired independently and not from the Disclosing Party (or Disclosing Party’s employees); 

(c) Is subsequently disclosed to the Receiving Party in good faith by a Third Party who is not under any obligation to maintain the
confidentiality of such information, and without breach of this Agreement by the Receiving Party; 
 (d) Has been published by a Third
Party as a matter of right; or 
 (e) Is independently developed by the Receiving Party’s employees who have not had access to the
Disclosing Party’s Confidential Information and without any use of or reliance upon information received from the Disclosing Party, as evidenced by the Receiving Party’s written records. 

  
 2 

 1.5 Equity Securities. The term “Equity Securities” shall mean any equity
securities of Licensee issued by Licensee for bona fide equity financing purposes, including, without limitation, equity securities of Licensee issued upon conversion of convertible debt of Licensee. 

1.6 Field. The term “Field” shall mean [***]. 

1.7 IND. The term “IND” shall mean an investigational new drug application, clinical trial application, clinical trial
exemption, or similar application or submission for approval to conduct human clinical investigations filed with or submitted to a regulatory authority in any country. 

1.8 Initiation. The term “Initiation” shall mean, with respect to a clinical trial, the first dosing of the first subject in
such trial. 
 1.9 Licensed Patent Rights. The term “Licensed Patent Rights” shall mean: 

(a) the patent applications listed in Exhibit A; 

(b) the foreign counterpart patent applications of the respective applications referenced in
sub-clause (a) above, but only to the extent the claims of such applications are entitled to the priority date of the respective applications referenced in
sub-clause (a) above; 
 (c) divisionals, substitutions, and continuations of any applications
referenced in sub-clauses (a) and (b) above that are entitled to the priority date of the respective applications referenced in sub-clause (a) above; 

(d) any claim(s) of a continuation-in-part application of any
application set forth in sub-clauses (a) and (c) above that are entitled to the priority date of the respective application(s) referenced in sub-clause
(a) above; 
 (e) the patents issued from the applications referenced in sub-clauses (a)-(c)
above and any reissues, reexaminations, renewals and patent term extensions of such patents; and 
 (f) any claim(s) of a patent issued
from a continuation-in-part application referenced in sub-clause (d) above that are entitled to the priority date of the
respective application(s) referenced in sub-clause (a) above, and any claim(s) of a reissue, reexamination, renewal and patent term extension of a patent issued from a continuation-in-part application referenced in sub-clause (d) above that are entitled to the priority date of the respective application(s) referenced in sub-clause (a) above. 
 At Licensee’s request from time to time, and in any event promptly
after the filing of any patent application within the “Patent Rights” (as defined in the RFOA) arising under the RFOA to which Licensee has timely exercised its option rights under the RFOA to take an exclusive license thereof, the parties
shall cooperate in good faith to compile a then-current list of the existing 

  
 3 

 
Licensed Patent Rights, which shall be signed by both parties, attached as Exhibit A to this Agreement, and incorporated herein by this reference. 

1.10 Licensed Product. The. term “Licensed Product” shall mean any product (i) the manufacture, use, sale, offer for
sale or importation of which would, in the absence of the license under the Licensed Patent Rights granted in this Agreement, infringe a Valid Claim of the Licensed Patent Rights, and/or (ii) that uses or incorporates any composition of matter
that is discovered or developed by TSRI under the RFOA using any methods disclosed in the Licensed Patent Rights and to which Licensee has exercised its option for an exclusive license under the RFOA. 

1.11 Licensed Technology. The term “Licensed Technology” shall mean the Licensed Patent Rights and Technical Information.

 1.12 Net Sales. The term “Net Sales” shall mean the gross amount invoiced by Licensee, its Affiliates or its
Sublicensees, or any of them (in each case, a “Selling Party”), to Third Parties on all sales of Products, less (a) discounts actually granted or allowed; (b) credits or allowances for claims, allowances, retroactive price
reductions, or rejected or returned goods; (c) rebates and chargebacks granted or allowed to managed health care organizations, [***], pharmacy benefit managers (or equivalents thereof), national, state/provincial, local, and other governments
and their agencies, and purchasers and reimbursers, or to trade customers; (d) transportation charges for the delivery of Products, including handling charges and insurance premiums relating thereto; (e) sales, use, excise or value added
taxes (except for any value added taxes that are reimbursable or reimbursed to the Selling Party) actually paid in connection with sales of Products (but excluding what are commonly known as income taxes or gross receipt taxes); (f) duties
imposed and paid on the import of Products for sale; and (g) a reasonable allowance for bad debts directly attributable to sales of Products, provided that such allowance shall not exceed [***] of Net Sales amounts for the applicable reporting
period. Licensee agrees to use, and to cause its Affiliates to use, commercially reasonable efforts to collect and enforce such bad debts from the debtors. 

Net Sales shall include all consideration charged by Licensee, its Affiliates or Sublicensees in exchange for any Products, including without
limitation any monetary payments or, with regard to any other property paid in exchange for any Products, an amount in cash equal to the fair market value of such property. For purposes of determining Net Sales, a sale shall be deemed to have
occurred when an invoice therefor is generated or the Product shipped for delivery. Sales of Products by one Selling Party to another Selling Party for resale shall be excluded, and only the subsequent sale of such Products to unrelated parties
shall be included in the calculation of Net Sales hereunder. Notwithstanding the foregoing, Products used in any clinical, pre-clinical or non-clinical research or
development activities, donated to non-profit institutions or government agencies, or provided in a sampling program or compassionate use program, in each case in which no monetary or other consideration is
paid to or received by Licensee, its Affiliates or any Sublicensee, shall be disregarded in determining Net Sales. 
 The deductible items
listed in sub-clauses (a)-(g) above shall be either (i) included as line items in the invoice, or (ii) reasonably supported by other appropriate 

  
 4 

 
documentation as being specifically attributable to actual sales of Products in accordance with U.S. Generally Accepted Accounting Standards (“GAAP”) or International Financing
Reporting Standards (“IFRS”), as applicable, consistently applied throughout the organization of the Selling Party., and the deductible item listed in sub-clause (g) above shall be taken
in accordance with GAAP or IFRS, as applicable, consistently applied throughout the organization of the Selling Party. If the Selling Party receives refunds or reimbursements of any amounts deducted as set forth herein, then such refunded or
reimbursed amounts shall be considered Net Sales in the applicable reporting period in which such refunded or reimbursed amounts are received. 

1.13 Other Product. The term “Other Product” shall mean any product that is not itself a Licensed Product but that:

 (a) is discovered or developed by Licensee or a Sublicensee using a method, the use of which would, in the absence of a license granted
by this Agreement, infringe any of the Licensed Patent Rights; or 
 (b) comprises, utilizes or incorporates Technical Information and/or
that is discovered or developed using Technical Information; or 
 (c) is generated by Licensee, either for its own account or in
collaboration with a Sublicensee (as defined in Section 1.21 below), through optimization of a Licensed Product or of a product meeting the definition of sub-clause (a) or (b) above. 

1.14 Phase 1 Trial. The term “Phase 1 Trial” shall mean a human clinical trial that would satisfy the requirements for a
Phase 1 study as defined in 21 CFR § 312.21(a) (or its successor regulation). 
 1.15 Phase 2 Trial. The term “Phase 2
Trial” shall mean a human clinical trial that would satisfy the requirements for a Phase 2 study as defined in 21 CFR § 312.21(b) (or its successor regulation). 

1.16 Phase 2a Trial. The term “Phase 2a Trial” shall mean a Phase 2 Trial constituting a preliminary efficacy study of a
candidate drug in the target patient population. 
 1.17 Phase 2b Trial. The term “Phase 2b Trial” shall mean a Phase 2
Trial constituting a dose exploration, dose response, duration of effect and kinetic/dynamic relationship study of a candidate drug in the target patient population. 

1.18 Phase 3 Trial. The term “Phase 3 Trial” shall mean a human clinical trial that would satisfy the requirements for a
Phase 3 study as defined in 21 CFR § 312.21(c) (or its successor regulation). 
 1.19 Principal Investigator. The term
“Principal Investigator” shall mean Dr. Benjamin Cravatt. 
 1.20 Product. The term “Product” shall mean a
Licensed Product and/or Other Product, as applicable. 

  
 5 

 1.21 Sublicensee. The term “Sublicensee” shall mean any Third Party to whom
Licensee grants a sublicense with respect to [***] under this Agreement, as contemplated by Section 2.2. The term “Sublicensee” shall also include any and all further Third Party Sublicensees that may be permitted under
Section 2.2. 
 1.22 Technical Information. The term “Technical Information” shall mean only the unpatented
information and data described in Exhibit B that are within the possession of the laboratory of the Principal Investigator at TSRI as of the Effective Date. 

1.23 Third Party. The term “Third Party” shall mean any entity other than TSRI or Licensee or any of their respective
Affiliates. 
 1.24 Total Royalty Burden, or TRB. The term “Total Royalty Burden” or “TRB” shall mean, with
respect to a Product, the sum of the Applicable Rate for such Product and the aggregate royalty rate at which Licensee is obligated to pay royalties to any and all Third Parties with respect to sales of such Product. 

1.25 Valid Claim. The term “Valid Claim” shall mean a claim of any issued and unexpired patent within the Licensed Patent
Rights which has not been held unenforceable, unpatentable or invalid by a decision of a court or governmental body of competent jurisdiction in a ruling that is unappealed or unappealable. The term “Valid Claim” shall also include the
claims of a pending patent application within the Licensed Patent Rights which have not been pending for a period of more than [***] years from the date of [***]. 

2. Grant of License. 

2.1 Grant of Exclusive License. TSRI hereby grants and Licensee accepts, subject to the terms and conditions of this Agreement, an
exclusive (except as set forth in Sections 2.4 and 2.5), worldwide, royalty-bearing license, under the Licensed Patent Rights and the Technical Information, to make, have made, use, have used, sell, have sold, offer for sale and import Products in
the Field. Licensee agrees not to practice or use the Licensed Patent Rights or Technical Information outside of the scope of the rights granted in this Section 2.1. 

2.2 Sublicensing. Licensee shall have the right to grant sublicenses (through multiple tiers of sublicense) with respect to the rights
conferred upon Licensee under this Agreement; provided, however, that any such sublicense shall be subject in all respects to the provisions contained in this Agreement (including without limitation the provisions regarding governmental
interest, reservation of rights, development efforts, reporting, audit rights, indemnity, warranty disclaimer, limitation of liability, confidentiality, and rights upon expiration or termination, but, for the avoidance of doubt, specifically
excluding Sections 3.1, 3.2 and 3.3). In the event of a conflict between this Agreement and the terms of any sublicense, the terms of this Agreement shall control. Licensee shall forward to TSRI a copy of any and all [***]. Licensee shall at all
times be and remain responsible for the compliance of Sublicensees with the terms and conditions of this 

  
 6 

 
Agreement, including without limitation payment of all amounts that may become due hereunder as a result of Sublicensees’ activities. 

2.3 No Other License. This Agreement confers no license or rights by implication, estoppel, or otherwise under any patent applications
or patents of TSRI other than Licensed Patent Rights regardless of whether such patents are dominant or subordinate to Licensed Patent Rights. 

2.4 Governmental Interest. Licensee and TSRI acknowledge that TSRI has received, and expects to continue to receive, funding from the
United States Government in support of TSRI’s research activities. Licensee and TSRI acknowledge and agree that, to the extent the Licensed Technology arises or results from TSRI’s receipt of research support from the United States
Government, their respective rights and obligations pursuant to this Agreement shall be subject to the rights of the United States Government, existing and as amended, including but not limited to, 37 CFR 401, the NIH Grants Policy Statement and the
NIH Guidelines for Obtaining and Disseminating Biomedical Research Resources. The United States Government shall have, among other rights, a non-exclusive,
non-transferable, irrevocable, paid-up license to practice or have practiced for or on behalf of the United States, the Licensed Technology that received research
support from the United States Government. 
 2.5 Reservation of Rights. Notwithstanding the exclusive license granted herein to the
Licensed Patent Rights and the Technical Information, TSRI reserves the right to use solely for any internal research or educational purposes any Licensed Patent Rights and Technical Information (specifically excluding any license or right to sell,
have sold or offer for sale any Product), without TSRI being obligated to pay Licensee any royalties or other compensation. In addition, TSRI reserves the right to grant non-exclusive, internal, non-commercial research and educational use licenses to other nonprofit or academic institutions to Licensed Patent Rights and Technical Information (specifically excluding any license or right to sell, have sold or
offer for sale any Product), without the other nonprofit or academic institution being obligated to pay Licensee any royalties or other compensation. Upon Licensee’s written request from time to time, but not more frequently than once per
calendar quarter, TSRI agrees to disclose to Licensee the identities of all nonprofit or academic institutions to which TSRI has granted any such license under the Licensed Patent Rights or the Technical Information. 

3. Royalties 
 3.1
Equity Grant. As consideration for the rights and licenses granted by TSRI to Licensee under this Agreement, within [***] days of the Effective Date, and subject to TSRI’s execution of a stock issuance agreement acceptable to Licensee,
Licensee shall issue and deliver to TSRI a number of shares of common stock of Licensee, which number of shares shall be equal to [***] (the “Agreed Percentage”) of the Fully Diluted Shares (as defined below) of Licensee, as of the
Effective Date (the “Initial Issuance”). Licensee’s failure to timely issue and deliver such Initial Issuance to TSRI, and which failure continues for an additional [***] days after Licensee’s receipt of TSRI’s
written notice regarding such failure, shall render this Agreement null and void (ab initio). Licensee further agrees that within [***] days of each sale of Equity Securities, whether in one transaction or a series of transactions,
which occurs after 

  
 7 

 
the Initial Issuance until Licensee receives aggregate gross proceeds from the sale of Equity Securities of [***] (the “Funding Threshold”), and subject to execution of a stock
issuance agreement acceptable to Licensee, Licensee shall issue and deliver to TSRI such additional number of shares of common stock of Licensee as necessary so that the total number of shares of Licensee common stock held by TSRI and its
transferees shall be equal to the Agreed Percentage of the Fully Diluted Shares as of the date of each such issuance of Equity Securities until Licensee has received total gross proceeds from sales of Equity Securities in an amount equal to the
Funding Threshold (“Additional Issuance”). Licensee’s failure to timely issue and deliver each such Additional Issuance to TSRI within the [***] day period referenced above, and which failure continues for an additional [***]
days after Licensee’s receipt of TSRI’s written notice regarding such failure, shall give TSRI the right to immediately terminate this Agreement. For the avoidance of doubt, the aggregate amount of gross proceeds from Licensee’s sale
of shares of its Series A preferred stock and common stock prior to the Effective Date (the “Proceeds”) counts towards the Funding Threshold. If Licensee issues debt or other similar securities (other than Equity Securities)
convertible into Equity Securities, then the Equity Securities shall be deemed sold, and payment received for issuance of such Equity Securities, when such Equity Securities are issued upon conversion of such debt or other securities. For
clarification, if the gross proceeds from the Licensee’s sale of Equity Securities exceed the Funding Threshold, the Additional Issuance issuable hereunder shall be issued only with respect to the first [***] of Equity Securities (including the
Proceeds) issued by the Licensee. For purposes of this Agreement, “Fully Diluted Shares” shall mean (i) all of the issued and outstanding shares of common stock, preferred stock (calculated on an
as-converted to common stock basis) and other capital stock of Licensee (calculated on an as-converted to common stock basis); (ii) all shares of common stock, preferred
stock and other capital stock of Licensee (calculated on an as-converted to common stock basis) issuable upon conversion of any outstanding security convertible, with or without consideration, into any common
stock, preferred stock or other equity security of Licensee; (iii) all shares of common stock, preferred stock and other capital stock of Licensee (calculated on an as-converted to common stock basis)
issuable upon conversion of any outstanding security or other agreement carrying or including any warrant or right to subscribe to or purchase any common stock, preferred stock or other equity security of Licensee; and (iv) all shares of common
stock, preferred stock and other capital stock of Licensee (calculated on an as-converted to common stock basis) issuable upon conversion of any issued and outstanding options and warrants to purchase common
stock, preferred stock or other equity security of Licensee (calculated on an as-exercised, as converted to common stock basis), provided that in no event shall any shares of common stock, preferred stock or
other capital stock of Licensee be counted more than once for purposes of calculating “Fully Diluted Shares”. The Initial Issuance and Additional Issuances to TSRI are [***]. The parties agree that TSRI shall not be obligated at any time
to make any representations or warranties on behalf of Licensee or to be liable in any way for any of Licensee’s representations, warranties, covenants or other agreements in connection with any sale, merger, reorganization, change in control,
disposition or other transaction involving Licensee except to the extent such representations or warranties solely relate to TSRI’s right to grants the licenses set forth in this Agreement. 

  
 8 

 3.2 Participation in Future Private Equity Offerings. If, after achievement of the
Funding Threshold but before the earlier of (a) the initial public offering of Licensee’s securities and (b) a sale of all or substantially all of Licensee’s business to which this Agreement relates, whether by merger, sale of
stock, sale of assets or otherwise, Licensee proposes to sell any Equity Securities for cash (a “Qualified Financing”), then[***] TSRI shall have the right, but not the obligation, to participate in such Qualified Financing, on the
same terms made available to all other investors in such Qualified Financing, to the extent necessary to maintain TSRI’s percentage ownership interest of Licensee’s Fully Diluted Shares. Notwithstanding the foregoing, no issuance of Equity
Securities of Licensee to any financial institution, [***], lessor or other entity in connection with any commercial credit arrangement, equipment financing, real property leasing arrangement, debt financing, [***] or similar transaction, that, in
each case, has been approved by Licensee’s board of directors, shall be considered a Qualified Financing. 
 3.3 Corporate
Updates. Before the earlier of (a) the initial public offering of Licensee’s securities and (b) a sale of all or substantially all of Licensee’s business to which this Agreement relates, whether by merger, sale of stock, sale
of assets or otherwise, upon TSRI’s written request from time to time (but no more than twice per year), an officer of Licensee shall provide to TSRI, either in person or via teleconference or videoconference, a corporate update regarding
Licensee’s business, finances, technology, and product candidates. Licensee reserves the right to limit the information disclosed to TSRI as Licensee, in the exercise of its business judgment, determines is necessary to preserve the
attorney-client privilege, to protect highly confidential proprietary information, or otherwise to protect the interests of Licensee and its stockholders. TSRI shall be subject to confidentiality obligations as set forth in Section 11.1 with
respect to any confidential information provided to or learned by it or any of its representatives in connection with TSRI’s exercise of the right granted in this Section 3.3. 

3.4 Minimum Annual Royalty. Licensee agrees to pay and shall pay to TSRI a nonrefundable minimum annual royalty in the amount of [***].
The first payment is due no later than [***], and subsequent payments are due [***] of each subsequent calendar year; provided, however, that the minimum annual payment obligation for a calendar year will be waived if [***]. Such payments
shall be credited against running royalties due for that calendar year and Royalty Reports shall reflect such a credit. Such payments shall not be credited against milestone payments (if any), Sublicensing Payments (if any), or against royalties due
for any preceding or subsequent calendar year. 
 3.5 Running Royalties. Licensee agrees to pay and shall pay to TSRI running
royalties on a country by country and Product by Product basis at the applicable rates set forth below: 
 (a) [***]; 

  
 9 

 (b) [***]; and 

(c) If no U.S. Licensed Patent Rights are allowed within [***] from the date of first examination on the merits of the applicable patent
application, and/or upon the expiration of the last to expire Valid Claim of the U.S. Licensed Patent Rights and until [***] of the first commercial sale of a particular Licensed Product in the United States [***] (provided that the last to expire
Valid Claim of the U.S. Licensed Patent Rights expires prior to such [***]), the parties agree that in recognition of Licensee’s use of the Technical Information and the significant value of the same to Licensee’s research, discovery,
development and manufacture of Licensed Products and Other Products, the royalty rate set forth above in subclause (b) shall apply (except, under the scenario in this sentence, for an Other Product covered by Section 1.13(a), in which
event the royalty rate shall be [***] of each Section 1.13(a) Other Product). For clarity, if the last to expire Valid Claim of the U.S. Licensed Patent Rights continues in existence beyond [***] of a particular Licensed Product (i.e., has not
expired prior to [***]), the royalty rate in subclause (b) above [***]. 
 3.6 Royalty Credit. If the Total Royalty Burden with
respect to a Product exceeds [***] the Applicable Royalty Rate for such Product (“[***] ARR”), then the rate at which Licensee is obligated to pay royalties to TSRI on Net Sales of such Product (“Adjusted Royalty
Rate”) shall be [***], provided that in no event shall the Adjusted Royalty Rate be [***]. For purposes hereof, the [***] shall mean [***]. The following hypothetical examples of the operation of this Section 3.6 are provided solely
for purposes of illustration. In both examples, the Product is a Licensed Product, and therefore the Applicable Royalty Rate is [***] and [***] is [***]. 
  

											
	 	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 Example 1
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 Example 2
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]

 3.7 Royalty Increase in the Event of a Challenge. 

(a) In the event Licensee or an Affiliate or a Sublicensee directly or indirectly institutes or makes any Challenge, the royalty payment
obligations specified in Section 3.5 of this Agreement (as adjusted in accordance with Section 3.6, if applicable) shall be [***] from the date such challenging party first institutes or makes such Challenge and during the pendency of such
Challenge and shall continue to apply after the conclusion of such Challenge in the event that [***] Valid Claim being challenged that covers a Licensed Product is held to be valid or enforceable. 

  
 10 

 (b) In the event Licensee, an Affiliate or Sublicensee directly or indirectly institutes or
makes any Challenges, Licensee shall have no right to recoup, recover, set off or otherwise get reimbursement of any royalties, equity, Sublicense Payments, milestone payments, patent costs or other monies paid hereunder during the period of such
Challenges. Licensee hereby voluntarily and irrevocably waives any right to seek return of such royalties, Sublicense Payments, milestone payments, patent costs or other monies in the event Licensee, an Affiliate or Sublicensee directly or
indirectly institutes or makes any Challenges. 
 (c) Licensee will provide written notice to TSRI at least [***] prior to Licensee or an
Affiliate instituting or making any Challenge. Licensee will include with such written notice a list of all prior art and a summary description of other facts and arguments that support its contention that any of the Licensed Patent Rights are
invalid or unenforceable to enable the parties to attempt in good faith to mutually resolve such issues. 
 (d) The parties agree that the
provisions of this Section 3.7 are reasonable and reflect a mutual adjustment of certain financial provisions of this Agreement to accommodate those situations in which a Challenge is made against TSRI in lieu of increasing the percentage rates
for royalties under Section 3.5 of this Agreement as of the Effective Date. 
 3.8 No Multiple Royalties. No multiple royalties
shall be due because any Licensed Product is covered by more than one of the Licensed Patent Rights. In such case, Licensee shall pay only one royalty at the applicable rate pursuant to Section 3.5 above. 

3.9 Ann’s-Length Transactions. On sales of Products which are made in other than an arm’s-length transaction, the value of the Net Sales attributed under this Section 3 to such a transaction shall be that which would have been received in an
arm’s-length transaction, based on sales of like quality and quantity products on or about the time of such transaction. 

3.10 Duration of Royalty Obligations. 

(a) Licensed Products. The royalty obligations of Licensee as to each Licensed Product shall terminate on a country-by-country basis upon expiration of the last-to-expire Valid Claim of the Licensed
Patent Rights that covers such Licensed Product in such country; provided, however, that if the termination date for Licensee’s royalty obligations with respect to a Licensed Product in a country occurs prior to [***] of such Product in
such country, then such Product shall be deemed an Other Product for purposes of Section 3.5 from such termination date until [***] of such Product in such country. 

(b) Other Products. The royalty obligations of Licensee as to each Other Product shall terminate on a
country-by-country basis on [***] of the first commercial sale of such Other Product in such country. 

4. Non-Royalty Revenues. 

4.1 Sublicense Payments. For purposes of this Agreement, “Sublicense Revenues” shall mean all revenues and other
amounts actually received by Licensee and its 

  
 11 

 
Affiliates from Sublicensees in consideration of the grant by Licensee or its Affiliate to a Sublicensee [***], including, without limitation, up-front
fees, license fees, maintenance fees, milestone payments, technology access fees, premiums above the fair market value on sales of debt or equity securities of Licensee or its Affiliate; but excluding: [***]. Any
non-cash Sublicense Revenues received by Licensee from a Sublicensee shall be valued at its fair market value as of the date of receipt, as determined in good faith by Licensee. Licensee shall pay to TSRI a non-creditable, non-refundable percentage of these Sublicense Revenues according to the following schedule (“Sublicense Payments”): 

 

			
	 Date of Sublicense Grant
	  	Percentage of Sublicense
Revenues Payable to TSRI
	 [***]
	  	[***]%
	 [***]
	  	[***]%
	 [***]
	  	[***]%

 “Completion of First Phase 2” means issuance of the draft study report from the first Phase 2a Trial of a
Product covered by such sublicense (regardless of whether or not endpoints are achieved). 
 Any milestone payment that Licensee makes to TSRI under
Section 4.3 below upon achievement of a given milestone event by a Sublicensee will be [***]. 
 4.2 Marketing Payments. In the
event that Licensee grants to a Third Party that is not an Affiliate or a Sublicensee the right only to market or promote any Product, but not any right to develop, sell or distribute such Product, and such Third Party makes payments to Licensee in
consideration of the grant of such marketing or promotion right (“Marketing Payments”), then 

  
 12 

 
Licensee agrees to pay to TSRI in accordance with Section 5.1 a non-creditable, non-refundable amount equal to
[***] of such Marketing Payments. 
 4.3 Product Development Milestones. Licensee agrees to pay and shall pay to TSRI the following non-creditable (except to the extent set forth in Section 4.1), non-refundable payments for the first achievement of the product development milestone events specified
below by each Product within [***] of such achievement; provided, however, [***]: 
  

					
	 Milestone
	  	Payment (US$)	 
	Initiation of first Phase 1 Trial of a Product	  	$	[***]	 
	Initiation of first Phase 2b Trial of a Product	  	$	[***]	 
	Initiation of first Phase 3 Trial of a Product	  	$	[***]	 
	First U.S. NDA approval for a Product	  	$	[***]	 

 For clarification, [***]. 

5. Royalty, Sublicense and Marketing Payments. 

5.1 Sales by Licensee; Sublicense and Marketing Payments. Licensee agrees to pay and shall pay to TSRI, within [***] after the end of
each calendar quarter, royalties under Section 3.5 (as adjusted in accordance with Section 3.6 and/or Section 3.7, if applicable) on Net Sales of Products by Licensee and its Affiliates during such calendar quarter, Sublicense
Payments under Section 4.1 on Sublicense Revenues received by Licensee and its Affiliates during such calendar quarter, and payments under Section 4.2 on Marketing Payments received by Licensee during such calendar quarter. 

5.2 Sales by Sublicensees. Licensee agrees to pay and shall pay to TSRI, or cause its Sublicensees that are not Affiliates of Licensee
to pay to TSRI, within [***] after the end of each calendar quarter, royalties under Section 3.5 (as adjusted in accordance with Section 3.6 and/or Section 3.7, if applicable) on Net Sales of Products by Sublicensees during such
calendar quarter. 
 6. Reports; Development and Commercialization Activities. 

6.1 Development Efforts. Licensee shall use commercially reasonable efforts and due diligence, itself and/or through one or more
Affiliates or Sublicensees, to conduct research and development of Products, as promptly as is reasonably and commercially feasible, and, subject 

  
 13 

 
to obtaining necessary regulatory approvals, to produce and sell reasonable quantities of Products. Licensee shall keep TSRI generally informed as to Licensee’s progress in such research,
development, regulatory approval, production and sale, including its efforts, if any, to sublicense Licensed Technology, and Licensee shall deliver to TSRI [***] written report of such efforts by [***] of each calendar year. Without limiting the
foregoing, Licensee shall report to TSRI achievement of the events described on Exhibit C. The parties hereto acknowledge and agree that achievement of the milestones described in Exhibit D attached hereto on or before the dates set
forth therein shall be evidence of compliance by Licensee with its development obligations hereunder for the time periods specified in Exhibit D. However, TSRI acknowledges that the drug discovery and development process is inherently
uncertain and involves high risks of failure; that, based on results generated through the practice of the Licensed Technology, Licensee may need to alter the course of its Product research and development efforts; and that many factors beyond the
reasonable control of Licensee may delay or prevent Licensee from achieving the milestones by the specified dates. Accordingly, Licensee may amend Exhibit D upon written consent by TSRI, such consent not to be unreasonably withheld, if
Licensee reasonably demonstrates to TSRI that Licensee has used commercially reasonable efforts at diligence in its performance of research and development of Products. In the event that Licensee has not achieved the milestones within the time
provided in Exhibit D (as may be amended as provided above), TSRI has the right to terminate this Agreement upon ninety (90) days’ prior written notice to Licensee unless, prior to the end of such
90-day period, Licensee reasonably demonstrates to TSRI that Licensee has used commercially reasonable efforts at diligence in its performance of research and development of Products and to achieve the
milestones within the time provided in Exhibit D. For clarification, failure to achieve the milestones within the time provided in Exhibit D (as may be amended as provided above) shall [***], but this sentence shall not otherwise affect or
limit TSRI’s termination rights in the preceding sentence. 
 6.2 Reports on Revenues and Payments. Following the earlier of
(a) the first commercial sale of a Product by Licensee or its Affiliate and (b) [***], Licensee shall submit to TSRI at the time any payment is due in accordance with Section 5 a royalty report (the “Royalty Report”)
setting forth for such quarter: 
 (a) the number of units of Products sold by Licensee and its Affiliates, or by its Sublicensees, as
applicable; 
 (b) the gross amounts invoiced for such Products; 

(c) a reasonably detailed listing of any offsets pursuant to Section 3.6 and deductions used to determine Net Sales of Products pursuant
to Section 1.12, and any refunds or reimbursed amounts previously deducted which are deemed Net Sales pursuant to Section 1.12; 

(d) the amount of royalties due under Section 3.5, or if no royalties are due to TSRI for any quarterly period, the statement that no
royalties are due and an explanation of why they are not due for that quarterly period; 

  
 14 

 (e) the amount of Sublicense Revenues and Marketing Fees received by Licensee; 

(f) the amount of Sublicense Payments due under Section 4.1, or if no Sublicense Payments are due to TSRI for any quarterly period, the
statement that no Sublicense Payments are due and an explanation of why they are not due for that quarterly period; and 
 (g) any
Marketing Payments received by Licensee and payments thereon due under Section 4.2. 
 Such Royalty Report shall be certified as correct by an officer
of Licensee. 
 6.3 Royalty Payments. Licensee agrees to pay and shall pay to TSRI with each Royalty Report the amount of royalties
and other payments due with respect to such quarter. Licensee shall specify which Licensed Patent Rights are utilized for each Licensed Product included in the Royalty Report. All payments due hereunder shall be deemed received when funds are
credited to TSRI’s bank account and shall be payable by check or wire transfer in United States Dollars. 
 6.4 Foreign Sales.
The remittance of royalties payable on sales outside the United States shall be payable to TSRI in United States Dollar equivalents at the official rate of exchange of the currency of the country from which the royalties are payable, as quoted in
the Wall Street Journal for the last business day of the calendar quarter in which the royalties are payable. If the transfer of or the conversion into the United States Dollar equivalents of any such remittance in any such instance is not lawful or
possible, the payment of such part of the royalties as is necessary shall be made by the deposit thereof, in the currency of the country where the sale was made on which the royalty was based to the credit and account of TSRI or its nominee in any
commercial bank or trust company of TSRI’s choice located in that country, prompt written notice of which shall be given by Licensee to TSRI. 

6.5 Foreign Taxes. Any tax required to be withheld by Licensee under the laws of any foreign country for any royalties or other amounts
due hereunder or for the accounts of TSRI shall be promptly paid by Licensee for and on behalf of TSRI to the appropriate governmental authority, and Licensee shall furnish TSRI with proof of payment of such tax together with official or other
appropriate evidence issued by the applicable government authority. Any such tax actually paid on TSRI’s behalf shall be deducted from royalty payments due TSRI. 

7. Record Keeping. Licensee shall keep, and shall require its Affiliates and Sublicensees to keep, accurate records (together with
supporting documentation) of sales of Products, as appropriate to enable determination of the amount of royalties, Sublicense Payments, payments under Section 4.2, Product Development Milestone Payments and other monies due to TSRI hereunder.
Such records shall be retained for at least [***] following the end of the reporting period to which such records relate. Such records shall be available, upon at least [***] days prior written notice to Licensee, during normal business hours for
examination and copying by an independent certified public accounting firm selected by TSRI and approved by Licensee, such approval not to be unreasonably withheld, for the purpose of verifying Licensee’s

  
 15 

 
Royalty Reports and payments are in compliance with this Agreement. In conducting such examinations pursuant to this Section 7, TSRI’s accountant shall have access to all records which
such accountant reasonably believes to be relevant to the calculation of royalties under Section 3, non-royalty revenues under Section 4 and Licensee’s compliance with its other financial
obligations under this Agreement. Such accountant will agree in its engagement agreement with TSRI to keep such records of Licensee, its Affiliates and Sublicensees confidential. Such accountant may disclose to TSRI its audit report and any
information, including, without limitation, work papers, notes, interim reports and other work product of the accountant (but excluding any direct source documents of Licensee or any Sublicensee), that the accountant reasonably believes to be
relevant to the calculation of royalties under Section 3, non-royalty payments under Section 4, and other financial obligations under this Agreement, provided that all of such information that such
accountant discloses to TSRI shall be concurrently disclosed to Licensee. The contents of the accountant’s audit report (and any accompanying information permitted hereunder to be provided therewith) shall be deemed to be Licensee’s
Confidential Information. Such accountant will send a copy of the report to Licensee at the same time it is sent to TSRI. The report sent to both parties will include the methodology and calculations used to determine the results. Such examination
shall be at TSRI’s expense, except that if such examination shows an underreporting or underpayment in excess of [***] for any twelve (12) month period, then Licensee shall pay the cost of such examination, as well as any additional
payments that would have been payable to TSRI under this Agreement had Licensee reported correctly, plus interest on said sum at the rate of [***]. All payments due hereunder shall be made within [***] days of Licensee’s receipt of a copy of
the audit report. TSRI may exercise its right of audit under this Section 7 no more frequently than once in any calendar year, and no calendar year shall be subject to audit under this Section 7 more than one time. The audit shall be
conducted by TSRI in a manner that is anticipated to not unreasonably interrupt or otherwise unreasonably interfere with Licensee’s business operations. 

8. Patent Matters. 
 8.1
Patent Prosecution and Maintenance. From and after the date of this Agreement, the provisions of this Section 8 shall control the prosecution of any patent application and maintenance of any patent included within Licensed Patent Rights.
Subject to the requirements, limitations and conditions set forth in this Agreement, TSRI shall (a) direct and control the preparation, filing and prosecution of the United States and foreign patent applications within Licensed Patent Rights
(including without limitation any reissues, reexaminations, appeals to appropriate patent offices and/or courts, interferences and foreign oppositions); and (b) maintain the patents issuing therefrom. TSRI shall select the patent counsel,
subject to Licensee’s written approval which shall not be unreasonably withheld, and TSRI may also use its Office of Patent Counsel to assist in such activities, and the fees and expenses associated with such work done by TSRI’s Office of
Patent Counsel and independent patent counsel shall be paid as set forth below. Licensee shall have full rights of consultation with the patent counsel so selected on all matters relating to Licensed Patent Rights. TSRI shall, and shall cause its
patent counsel to, use reasonable efforts to implement all reasonable and timely requests made by Licensee with regard to the preparation, filing, prosecution and/or maintenance of the patent applications and/or patents within Licensed Patent
Rights; provided, however, that in the event of a disagreement between TSRI and 

  
 16 

 
Licensee with respect to any such patent prosecution or maintenance matters, TSRI shall have the final decision making authority over all such matters. If requested by Licensee, TSRI shall also
consider in good faith, to the extent feasible, segregating such claims suggested by Licensee in a divisional or other form of continuation application. Subject to Licensee’s payment of patent expenses with respect to a Licensed Patent Right in
accordance with Section 8.3, TSRI shall not abandon or otherwise decline to prosecute and maintain such Licensed Patent Right without Licensee’s prior written consent. If, for any reason, TSRI nonetheless wishes to abandon or otherwise
decline to prosecute and maintain any Licensed Patent Right, TSRI shall so notify Licensee in writing (which notice shall, in any event, be given no later than 60 days prior to the next deadline for any action that may be taken with respect to such
Licensed Patent Right with the U.S. Patent and Trademark Office or any foreign patent office), in which event Licensee shall have the right to assume responsibility for prosecution and maintenance of such Licensed Patent Right in TSRI’s name,
at Licensee’s sole expense, and TSRI shall take such actions and execute such instruments as may be necessary for Licensee to prosecute and maintain such Licensed Patent Right. 

8.2 Information to Licensee. TSRI shall keep Licensee timely informed with regard to the patent application and maintenance processes.
TSRI shall deliver to Licensee copies of all patent applications, amendments, related correspondence, and other related matters in a timely manner. Without limiting the foregoing, TSRI shall provide or ensure that patent counsel provides Licensee
[***] updated patent prosecution and maintenance schedule for all patent applications and patents within the Licensed Patent Rights. 
 8.3
Patent Costs. Licensee agrees to pay and shall pay TSRI for all expenses referenced in Sections 8.1 hereof within [***] days after Licensee receives an itemized invoice therefor. Failure of Licensee to pay patent costs and expenses as set
forth in this Section 8.3 shall immediately relieve TSRI from its obligation to incur any further patent costs and expenses. For the avoidance of doubt, should Licensee not pay any patent costs and expenses due to TSRI within [***] days after
Licensee’s receipt of any itemized invoice therefor, TSRI shall have the right, at its sole discretion following [***] days prior written notice to Licensee, to cease all patent prosecution and allow Licensed Patent Rights to go abandoned. Such
action by TSRI shall not constitute a breach of this Agreement. Licensee may elect with a minimum of [***] days prior written notice to TSRI, to discontinue payment for expenses incurred by TSRI with regard to the filing, prosecution and/or
maintenance of any patent application and/or patent within such Licensed Patent Rights. Licensee shall remain liable for all patent prosecution and maintenance costs incurred prior to the date of notice of election and for a [***] day period
following date of such notice. Any such patent application or patent so elected shall immediately be excluded from the definition of Licensed Patent Rights and from the scope of the licenses granted under this Agreement, and all rights relating
thereto shall revert to TSRI and may be freely licensed by TSRI. 
 8.4 Ownership. The patent applications filed and the patents
obtained by TSRI pursuant to Section 8.1 hereof shall be owned solely by TSRI, assigned solely to TSRI and deemed a part of Licensed Patent Rights. For the avoidance of doubt, all patent applications filed by Licensee covering Licensee’s
Products, Other Products or other Licensee inventions unrelated to the subject matter of this Agreement (as to which no TSRI employee is an inventor) shall be owned 

  
 17 

 
solely by Licensee. To the extent Licensee, either acting alone or jointly with TSRI, creates improvements to the Licensed Technology, Licensee shall assign all of its interest therein to TSRI
and TSRI agrees to treat such assigned improvements as Licensed Technology under this Agreement. 
 8.5 TSRI Right to Pursue Patent.
If at any time during the term of this Agreement, Licensee’s rights with respect to Licensed Patent Rights are terminated in accordance with the terms of this Agreement, TSRI shall have the right to take whatever action TSRI deems appropriate
to obtain or maintain the Licensed Patent Rights. If TSRI pursues patents under this Section 8.5, Licensee agrees to cooperate fully, including by providing, at no charge to TSRI, all appropriate technical data and executing all necessary legal
documents. 
 8.6 Infringement Actions. 

8.6.1 Prosecution and Defense of Infringements. In the event that either TSRI or Licensee becomes aware of any infringement or
threatened infringement by a Third Party of any Licensed Patent Rights, it shall notify the other party in writing to that effect. Licensee shall make good faith efforts to abate or terminate such infringement. Licensee shall have the first right
(but not the obligation) to bring and control any action or proceeding against a Third Party with respect to infringement (including patent invalidation and nullity actions) of any Licensed Patent Right, at its own expense and by counsel of its own
choice, and TSRI shall have the right, at its own expense, to be represented in any such action by counsel of its own choice. Licensee may enter into settlements, stipulated judgments or other arrangements respecting such infringement, at its own
expense, but only with the prior written consent of TSRI, which consent shall not be unreasonably withheld. TSRI shall permit any action to be brought in its name if required by law or to join any action as a necessary party if required for
prosecution of such action (which shall be a condition to any obligation of Licensee to prosecute infringement of any Licensed Patent Rights to the extent necessary to enable Licensee to do so), and Licensee shall hold TSRI harmless from any costs,
expenses or liability respecting all such infringement actions. TSRI agrees to provide reasonable assistance of a technical nature which Licensee may require in any litigation arising in accordance with the provisions of this Section 8.6.1, for
which Licensee shall pay to TSRI a reasonable hourly rate of compensation. If Licensee fails to bring any such action or proceeding within (A) [***] days following the notice of alleged infringement, or (B) [***] days before the time limit, if any,
set forth in the appropriate laws and regulations for the filing of such actions, whichever comes first, then TSRI shall have the right to bring and control any such action, at its own expense and by counsel of its own choice, and Licensee shall
have the right, at its own expense, to be represented in any such action by counsel of its own choice. 
 8.6.2 Allocation of
Recovery. Any damages, settlements or other recovery from an infringement action undertaken by Licensee pursuant to Section 8.6.1 shall first be used to reimburse the parties for the costs and expenses incurred in such action, and shall
thereafter be allocated between the parties as follows: (a) [***] to TSRI and (b) [***] to Licensee. If Licensee fails to prosecute any such action (at all or to completion) and TSRI elects to prosecute such action, then any damages, settlements, or
other recovery, net of the parties’ costs and expenses incurred in such infringement action, shall [***]. 

  
 18 

 9. Indemnity and Insurance. 

9.1 Indemnity. Licensee hereby agrees to indemnify, defend (by counsel reasonably acceptable to TSRI) and hold harmless TSRI and any
parent, subsidiary or other affiliated entity of TSRI, and their trustees, directors, officers, employees, scientists and agents, successors, assigns and other representatives (collectively, the “Indemnitees”) from and against all
damages, liabilities, losses and other expenses, including without limitation reasonable attorney’s fees, expert witness fees and costs incurred by the Indemnitees, as a result of any Third Party claim, whether or not a lawsuit or other
proceeding is filed (“Claim”), that arises out of or relates to (a) Licensee’s or any of its Affiliates’ or Sublicensees’ use of any of the Licensed Technology, (b) the research, development, manufacture,
use, offer for sale, sale, or importation of any Product by or on behalf of Licensee or any of its Affiliates or Sublicensees, (c) the negligent or willful acts or omissions of Licensee or any of its Affiliates or Sublicensees, (d) any
allegations that the Products developed, manufactured, sold, distributed or rendered by Licensee or any Affiliate or Sublicensee and/or any trademarks, service marks, logos, symbols, slogans, or other materials used in connection with or to market
Products violate or infringe upon the trademarks, service marks, trade secrets, trade dress, trade names, copyrights, patents, works of authorship, inventorship rights, database rights, rights under unfair competition laws, rights of publicity,
privacy or defamation, or any other intellectual or industrial property right of any Third Party, (e) Licensee’s, its Affiliate’s or any Sublicensee’s failure to comply with any applicable laws, rules or regulations in connection
with activities contemplated by this Agreement, and/or (f) Licensee’s, its Affiliate’s or any Sublicensee’s labeling, packaging or patent marking of any Product or containers thereof. In each case, Licensee’s liability for
damages under its indemnity shall be reduced or apportioned to the extent such Claim was proximately caused by TSRI’s or any Indemnitee’s gross negligence or willful misconduct or TSRI’s breach of its representation and warranty under
Section 10.1. Licensee shall not enter into any settlement of such Claims that involve TSRI admitting any liability, paying any money or taking any action that would have an adverse effect on TSRI’s reputation or business without
TSRI’s prior written consent. In the event an Indemnitee seeks indemnification with respect to a Claim under this Section 9.1, it shall inform Licensee of such Claim as soon as reasonably practicable after it receives notice of such Claim,
shall permit Licensee to assume direction and control of the defense of the Claim (including the right to settle the Claim solely for monetary consideration, subject to the limitations of the preceding sentence) using counsel selected by Licensee
and reasonably acceptable to TSRI, and shall cooperate as reasonably requested (at the expense of Licensee) in the defense of the Claim. Notwithstanding the above, Indemnitees, at their expense, shall have the right to retain separate independent
counsel to assist in defending any such Claims. In the event Licensee fails to timely indemnify and defend such Claims and/or pay Indemnitees’ expenses as provided above, Indemnitees shall have the right to defend themselves, and in that case,
Licensee shall reimburse Indemnitees for all of their reasonable attorney’s fees, costs and damages incurred in settling or defending such Claims within [***] days of each of Indemnitees’ written requests. This indemnity shall be a direct
payment obligation and not merely a reimbursement obligation of Licensee to Indemnitees. 
 9.2 Insurance. Licensee shall name TSRI
and Indemnitees as additional insured parties on any commercial general liability and product liability insurance policies maintained by Licensee, its Affiliates, and Sublicensees applicable to the Products. 

  
 19 

 9.2.1 Beginning at the time any such Product is being commercially distributed or sold
(other than for the purpose of obtaining regulatory approvals) by Licensee or by a Sublicensee, Licensee shall, at its sole cost and expense, procure and maintain commercial general liability insurance in amounts and on terms consistent with
industry standards for similarly situated pharmaceutical companies commercializing products, but in no case will such insurance be less than $[***] per incident and $[***] annual aggregate with defense costs covered in addition to these limits.
During clinical trials involving any Product, Licensee shall, at its sole cost and expense, procure and maintain commercial general liability insurance in amounts and on terms consistent with industry standards for similarly situated pharmaceutical
companies conducting clinical trials of products, but no less than $[***] per occurrence and $[***] annual aggregate. Such commercial general liability insurance shall provide (i) product liability or completed operations/clinical trial
coverage, as applicable; and (ii) broad form contractual liability coverage. Licensee may elect to self-insure all or part of the foregoing on commercially reasonable terms. Such self-insurance must be approved by TSRI; however, automatic
approval shall occur if the market capitalization of Licensee reaches or exceeds [***]. The insurance coverage amounts specified herein or the maintenance of such insurance policies shall not in any way limit Licensee’s indemnity or other
liability under this Agreement. 
 9.2.2 In addition, Licensee, on behalf of itself and its insurance carriers, waives any and all rights of
subrogation with respect to either party’s performance under this Agreement or for any loss of or damage to Licensee or its property or the property of others under its control. Licensee’s commercial general liability insurance policy
shall also include a waiver of subrogation consistent with this paragraph in favor of TSRI and the Indemnitees. Licensee shall be responsible for obtaining such waiver of subrogation from its insurance carriers. Licensee’s insurance policies
shall be primary and not contributory to any insurance carried by its Sublicensees or TSRI. Upon TSRI’s request, Licensee shall deliver to TSRI copies of insurance certificates or binders and such waiver of subrogation that complies with the
requirements of this Section 9.2.2. Licensee shall provide TSRI with written notice at least fifteen (15) days prior to the cancellation, non-renewal or material adverse change in such insurance
described in Section 9.2.1. 
 9.2.3 Licensee shall maintain such commercial general liability insurance beyond the expiration or
termination of this Agreement during (a) the period that any Product is being commercially distributed or sold by Licensee or by a Sublicensee, Affiliate or agent of Licensee; and (b) a reasonable period after the period referred to in
clause (a) of this Section 9.2.3, which in no event shall be less than five (5) years. 
 10. Limited Warranty. 

10.1 Limited Warranty. TSRI hereby represents and warrants that: (a) it has full right and power to enter into this Agreement and
to grant the licenses and rights granted to Licensee herein. 
 10.2 Disclaimer. EXCEPT AS PROVIDED IN SECTION 10.1, NEITHER PARTY
MAKES ANY WARRANTIES CONCERNING LICENSED TECHNOLOGY, PRODUCTS OR ANY OTHER MATTER WHATSOEVER, INCLUDING WITHOUT 

  
 20 

 
LIMITATION ANY EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NON-INFRINGEMENT OF THIRD PARTY RIGHTS OR ARISING OUT OF
COURSE OF CONDUCT OR TRADE CUSTOM OR USAGE, AND DISCLAIMS ALL SUCH EXPRESS OR IMPLIED WARRANTIES. NEITHER PARTY MAKES ANY WARRANTY OR REPRESENTATION AS TO THE VALIDITY OR SCOPE OF LICENSED PATENT RIGHTS, OR THAT ANY PRODUCT WILL BE FREE FROM AN
INFRINGEMENT ON PATENTS OR OTHER INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES, OR THAT NO THIRD PARTIES ARE IN ANY WAY INFRINGING UPON ANY LICENSED PATENT RIGHTS OR OTHER LICENSED TECHNOLOGY COVERED BY THIS AGREEMENT. FURTHER, TSRI HAS MADE NO
INVESTIGATION AND MAKES NO REPRESENTATION THAT THE LICENSED TECHNOLOGY IS SUITABLE FOR LICENSEE’S PURPOSES. LICENSEE MAKES NO REPRESENTATION OR WARRANTY REGARDING THE SUCCESS OF EFFORTS TO DEVELOP AND COMMERCIALIZE PRODUCTS. 

10.3 Limitation of Liability. IN NO EVENT SHALL [***] BE LIABLE FOR ANY INDIRECT, SPECIAL, INCIDENTAL, EXEMPLARY OR CONSEQUENTIAL
DAMAGES (INCLUDING WITHOUT LIMITATION DAMAGES FOR LOSS OF PROFITS OR EXPECTED SAVINGS OR OTHER ECONOMIC LOSSES, OR FOR INJURY TO PERSONS OR PROPERTY) ARISING OUT OF OR IN CONNECTION WITH THIS AGREEMENT OR ITS SUBJECT MATTER; PROVIDED, HOWEVER,
THAT THIS SECTION 10.3 SHALL NOT BE CONSTRUED TO LIMIT LICENSEE’S INDEMNIFICATION OBLIGATIONS UNDER SECTION 9.1. TSRI’S AGGREGATE LIABILITY, IF ANY, FOR ALL DAMAGES OF ANY KIND RELATING TO THIS AGREEMENT OR ITS SUBJECT MATTER SHALL NOT
EXCEED THE AMOUNT PAID BY LICENSEE TO TSRI UNDER THIS AGREEMENT. THE FOREGOING EXCLUSIONS AND LIMITATIONS SHALL APPLY TO ALL CLAIMS AND ACTIONS OF ANY KIND AND ON ANY THEORY OF LIABILITY, WHETHER BASED ON CONTRACT, TORT (INCLUDING, BUT NOT LIMITED
TO NEGLIGENCE OR STRICT LIABILITY), OR ANY OTHER GROUNDS, AND REGARDLESS OF WHETHER A PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES, AND NOTWITHSTANDING ANY FAILURE OF ESSENTIAL PURPOSE OF ANY LIMITED REMEDY. THE PARTIES FURTHER AGREE
THAT EACH WARRANTY DISCLAIMER, EXCLUSION OF DAMAGES OR OTHER LIMITATION OF LIABILITY HEREIN IS INTENDED TO BE SEVERABLE AND INDEPENDENT OF THE OTHER PROVISIONS BECAUSE THEY EACH REPRESENT SEPARATE ELEMENTS OF RISK ALLOCATION BETWEEN THE PARTIES.

 11. Confidentiality and Publication. 

11.1 Treatment of Confidential Information. The parties agree that during the term of this Agreement, and for a period of [***] after
this Agreement terminates, a party receiving Confidential Information of the other party will (a) maintain in confidence such Confidential Information to the same extent such party maintains its own proprietary information; (b) not
disclose such Confidential Information to any Third Party without prior written consent of the other party; and (c) not use such Confidential Information for any purpose except those permitted by this Agreement. Notwithstanding the foregoing,
if a party is required by law, 

  
 21 

 
regulation or court order to disclose Confidential Information of the other party, the party required to make such disclosure shall limit the same to the minimum required to comply with the law
or court order, and shall use reasonable efforts to attempt to seek confidential treatment for that disclosure, and prior to making such disclosure that party shall notify the other party, not later than [***] days (or such shorter period of time as
may be reasonably practicable under the circumstances) before the disclosure in order to allow that other party to comment and/or to obtain a protective or other order, including extensions of time and the like, with respect to such disclosure. In
addition, a party may disclose Confidential Information of the other party to Affiliates, employees, or consultants, to Sublicensees and potential Sublicensees (in the case of Licensee), or to other Third Parties in connection with due diligence or
similar investigations by such Third Parties or potential Third Party investors in confidential financing documents, provided, in each case, that any such Affiliate, employee, consultant, Sublicensee, potential Sublicensee or other Third Party
agrees in writing to be bound by terms of confidentiality and non-use at least as stringent to those set forth in this Section 11, but with no further right to disclose or otherwise distribute the other
party’s Confidential Information. Notwithstanding the above, either party has the right to disclose Confidential Information to an organization to whom such party will or intends to assign or transfer this Agreement or, for TSRI, the payment
obligations due to TSRI under this Agreement for monetization purposes, provided that such organization agrees in writing to be bound by terms of confidentiality with respect to the Confidential Information at least as protective as those set forth
in this Section 11.1. 
 11.2 Publications. Licensee agrees that TSRI shall have a right to publish in accordance with its
general policies, and that, subject to TSRI’s compliance with Section 11.1 as it applies to Confidential Information of Licensee, this Agreement shall not restrict, in any fashion, TSRI’s right to publish. 

11.3 Publicity. Except as otherwise provided herein or required by any applicable law, rule or regulation (including, without
limitations, rules of the Securities and Exchange Commission and rules of any stock exchange upon which Licensee’s securities may be listed), no party shall originate or distribute any publication, news release or other public announcement,
written or oral, whether in the public press, stockholders’ reports, or otherwise, relating to this Agreement or to any sublicense hereunder, or to the performance hereunder or under any such sublicense agreements, without the prior written
approval of the other party, which approval shall not be unreasonably withheld. Scientific publications published in accordance with Section 11.2 of this Agreement shall not be construed as publicity governed by this Section 11.3. 

12. Term and Termination. 

12.1 Term. Unless terminated sooner in accordance with the terms set forth herein, this Agreement, and the license granted hereunder,
shall terminate upon termination of the royalty obligations as provided in Section 3.10 hereof. 
 12.2 Termination Upon Mutual
Agreement. This Agreement may be terminated by mutual written consent of both parties. 
 12.3 Termination by TSRI. TSRI may
terminate this Agreement as follows: 

  
 22 

 (a) If Licensee does not make a payment due hereunder and fails to cure such non-payment (including the payment of interest in accordance with Section 14.2) within thirty (30) days after the date of notice in writing of such non-payment by
TSRI; 
 (b) If Licensee defaults upon any of its material obligations hereunder (other than any payment obligation, which is subject to
Section 12.3(a)), including, without limitation, the indemnification or insurance obligations under Section 9, and does not cure such default within sixty (60) days after receipt of notice from TSRI specifying in reasonable detail the
nature of such default; 
 (c) As provided in Section 6.1; 

(d) Upon written notice to Licensee in the event of the filing for bankruptcy by Licensee, or determination by a court of competent
jurisdiction that Licensee is bankrupt, or the appointment of a receiver of any of Licensee’s assets, or the making by Licensee of any assignment for the benefit of creditors, or the institution of any proceedings against Licensee under any
bankruptcy law that are not dismissed or discharged within sixty (60) days after institution; 
 (e) If Licensee is convicted of a
felony relating to the development, manufacture, use, sale or marketing of Products; or 
 (f) In the event Licensee, its Affiliate or a
Sublicensee directly or indirectly institutes or makes any Challenges, TSRI has the right to immediately terminate this Agreement without any liability and without any opportunity to cure by Licensee, its Affiliate or Sublicensee upon written notice
to Licensee; provided, however, that if a Sublicensee directly or indirectly institutes or makes any Challenge: (i) TSRI shall have the right to terminate only that portion of the license granted to Licensee under Section 2.1 that
relates to the Product to which such Sublicensee has been granted a sublicense; and (ii) except as expressly provided in the preceding clause (i), this Agreement, including, without limitation, Licensee’s license under Section 2.1 and
all other sublicenses granted by Licensee thereunder, shall otherwise remain in full force and effect. 
 12.4 Termination by
Licensee. Licensee may terminate this Agreement by giving ninety (90) days advance written notice of termination to TSRI. 
 12.5
Rights Upon Expiration. Upon the expiration of this Agreement, the license granted to Licensee under Section 2.1 will become royalty-free, fully paid up, irrevocable and perpetual. Neither party shall have any further rights or
obligations upon the expiration of this Agreement upon its regularly scheduled expiration date other than the obligation of Licensee to make any and all reports and payments due under Article 3 and/or 4 and Section 12.8 with respect to events
that occurred prior to such expiration in accordance with Sections 6.2, 6.3, 6.4 and 6.5 and to reimburse patent fees and expenses incurred by TSRI prior to expiration in accordance with Section 8.3, and Licensee shall thereafter have no
further payment or reporting obligations to TSRI under Articles 3, 4 and 6 with respect to Products; provided, however, that upon such expiration, each party shall be required to continue to abide by its obligations as described in

  
 23 

 
Section 11 which shall survive such expiration. Sections 1, 23, 2.4, 2.5, 7 (for the period described therein), 9.1, 9.2 (for the period described therein), 10.2, 10.3, 12.5, 13 and 14 shall
also survive the expiration of this Agreement. 
 12.6 Rights Upon Termination. 

12.6.1 Notwithstanding any other provision of this Agreement, upon any termination of this Agreement prior to the regularly scheduled
expiration date of this Agreement, the licenses granted hereunder shall terminate and revert to TSRI. Except as otherwise provided in Section 12.7 of this Agreement with respect to
work-in-progress, upon such termination, Licensee shall have no further right to develop, manufacture, market or sell any Product, or to otherwise use any Licensed
Technology. Upon any such termination, Licensee shall promptly return all materials, samples, documents, information, and other materials which embody or disclose Licensed Technology; provided, however, that Licensee shall not be obligated to
provide TSRI with proprietary information which Licensee can show that it independently developed. Any such termination shall not relieve either party from any obligations accrued to the date of such termination, including without limitation the
obligation of Licensee to make any and all reports and payments due under Article 3 and/or 4 and Section 12.8 with respect to events that occurred prior to such termination or as provided in Section 12.7, in each case in accordance with
Sections 6.2, 6.3, 6.4 and 6.5, and to reimburse patent fees and expenses incurred by TSRI prior to termination in accordance with Section 8.3. Upon such termination, each party shall be required to abide by its obligations as described in
Section 11 which shall survive such termination. Sections 1, 2.3, 2.4, 2.5, 7 (for the period described therein), 9.1, 9.2 (for the period described therein), 10.2, 10.3, 12.6, 12.7, 13 and 14 shall also survive the termination of this
Agreement. 
 12.6.2 At the election of the applicable Sublicensee upon written notice to TSRI, the sublicense granted hereunder to such
Sublicensee that was in effect immediately prior to termination of this Agreement will survive such termination, with TSRI as the Sublicensee’s direct licensor, subject to the following conditions: 

(a) such Sublicensee is not then in default under its sublicense; 

(b) such Sublicensee (either alone or together with other Sublicensees electing to have their sublicenses survive the termination of this
Agreement) pays to TSRI all outstanding royalties and other monies owed by Licensee to TSRI under this Agreement; and 
 (c) within 60 days
after termination of this Agreement, such Sublicensee shall execute and deliver to TSRI, for signature by TSRI, a license agreement between such Sublicensee and TSRI (the “New License Agreement”), which New License Agreement shall
be subject to the same non-financial terms and conditions as those in this Agreement; provided, however, that each New License Agreement shall contain substantially the same terms and conditions
regarding sublicense scope, sublicense territory, duration of sublicense grant, and diligence obligations of the Sublicensee as the sublicense agreement between such Sublicensee and Licensee; and (i) Sublicensee shall agree in the New License
Agreement to terms providing that in no event shall TSRI be liable to Sublicensee for any actual or alleged breach of such sublicense agreement by Licensee; (ii) TSRI shall not have any obligations to such Sublicensee other than TSRI’s

  
 24 

 
obligations to Licensee as set forth herein; (iii) such New License Agreement shall be subordinate and comply in all respects to the applicable provisions of this Agreement; (iv) such
Sublicensee’s payment obligations with respect to its surviving license to the Licensed Technology shall be those set forth in this Agreement (and not those set forth in the sublicense agreement between such Sublicensee and Licensee); and
(v) in no event shall TSRI be obliged to accept provisions in the New License Agreement (A) unless such provisions correspond to rights granted by Licensee to Sublicensee in conformance with this Agreement, and such provisions are not in
conflict with the rights, duties and obligations accruing to Licensee under this Agreement; or (B) where such provisions are inconsistent with the legal obligations under any other sublicense agreement granted by Licensee, or by applicable
federal, state or local statute or regulation. Licensee must include or specifically reference this Section 12.6.2 in each of its sublicense agreements in order for such Sublicensee’s sublicense to survive termination of this Agreement.
For the avoidance of doubt, Licensee shall have no liability or obligation to TSRI under the New License Agreement. 
 12.7 Work-in-Progress. Upon any early termination of the license granted hereunder in accordance with this Agreement, Licensee shall be entitled to finish any work-in-progress and to sell any completed inventory of Products covered by such license which remain on hand as of the date of the termination, so long as Licensee sells such
inventory in the normal course of business and at regular selling prices and pays to TSRI the royalties applicable to said subsequent sales in accordance with the terms and conditions as set forth in this Agreement, provided that no such sales shall
be permitted after the expiration of six (6) months after the date of termination. 
 12.8 Final Royalty Report. Upon
termination or expiration of this Agreement, Licensee shall submit a final report to TSRI, and any payments due TSRI and unreimbursed patent expenses incurred by TSRI prior to such expiration or termination pursuant to Section 8.3 shall become
immediately payable. 
 13. Assignment; Successors. 

13.1 Assignment. Any and all assignments of this Agreement or any rights granted hereunder by Licensee without the prior written
consent of TSRI are void, except either party may assign this Agreement or rights granted hereunder without the prior written consent of the other party (i) to an Affiliate of the assigning party, or in the case of TSRI to any entity which
directly or indirectly controls, or is controlled by, TSRI (where “control” has the meaning set forth in Section 1.1 or the ability otherwise to direct the management and policies of TSRI); or (ii) to a successor in interest to
all or substantially all of the business or assets of the assigning party, whether by way of a merger, consolidation, sale of assets, sale of stock, or similar transaction. Notwithstanding the above, TSRI also has the right to assign this Agreement
or the Licensed Technology for monetization purposes or any or all of the payment obligations due to TSRI under this Agreement to any Third Party without Licensee’s prior written consent, provided that Licensee retains all rights set forth in
this Agreement and under the license to the Licensed Technology granted herein. 
 13.2 Binding Upon Successors and Assigns. Subject
to the limitations on assignment herein, this Agreement shall be binding upon and inure to the benefit of any successors 

  
 25 

 
in interest and assigns of TSRI and Licensee. Any such successor or assignee of Licensee’s interest shall expressly assume in writing the performance of all the terms and conditions of this
Agreement to be performed by Licensee and such written assumption shall be delivered to TSRI. Any such successor or assignee of TSRI’s interest shall expressly assume in writing the performance of all the terms and conditions of this Agreement
to be performed by TSRI and such written assumption shall be delivered to Licensee. 
 14. General Provisions. 

14.1 Independent Contractors. The relationship between TSRI and Licensee is that of independent contractors. TSRI and Licensee are not
joint venturers, partners, principal and agent, master and servant, employer or employee, and have no other relationship other than independent contracting parties. TSRI and Licensee shall have no power to bind or obligate each other in any manner,
other than as is expressly set forth in this Agreement. 
 14.2 Late Payments. Late payments of any and all payments due hereunder
shall be subject to a charge of one and [***], or [***] whichever is greater. 
 14.3 Governmental Approvals and Marketing of
Products. Licensee shall be responsible for obtaining all necessary governmental approvals for the development, production, distribution, performance, sale and use of any Product, at Licensee’s expense, including, without limitation, any
safety studies. Licensee shall have sole responsibility for any warning labels, packaging and instructions as to the use of Products and for the quality control for any Products. 

14.4 Patent Marking. To the extent required by applicable law, Licensee shall mark all Licensed Products or their containers in
accordance with the applicable patent marking laws. 
 14.5 No Use of Name. The use of the name “The Scripps Research
Institute”, “Scripps”, “TSRI” or any variation thereof in connection with the advertising, sale or performance of Products is expressly prohibited. 

14.6 U.S. Manufacture. To the extent required, Licensee agrees to abide by the Preference for United States Industry as set forth in 37
CFR 401.14 (I). 
 14.7 Foreign Registration. Licensee agrees to register this Agreement with any foreign governmental agency which
requires such registration, and Licensee shall pay all costs and legal fees in connection therewith. In addition, Licensee shall ensure that all foreign laws affecting this Agreement or the sale of Products are fully satisfied. 

14.8 Dispute Resolution. Any dispute or claim between the parties arising out of or relating to this Agreement, including without
limitation the breach thereof, shall be resolved according to the following dispute resolution procedures: 
 (a) Such dispute shall be
first addressed by the representatives of TSRI and Licensee who have primary responsibility for managing this Agreement. 

  
 26 

 (b) If the dispute is not resolved by such representatives within [***] days after the date
either party gives written notice that such dispute exists, then the dispute shall be referred to and addressed by the senior management of each party. 

(c) If such dispute is not resolved by the parties’ senior management within [***] days after the date the dispute is referred to them,
then the dispute shall be submitted to mediation. The mediator shall be a retired judge or other neutral Third Party mutually selected by TSRI and Licensee who has at least ten (10) years’ experience in mediating or arbitrating cases in
the bio-pharmaceutical industry and regarding the same or substantially similar subject matter as the dispute between Licensee and TSRI. If the parties are unable to agree on such mediator within [***] days
after they exchange initial lists of potential mediators, a mediator with the same qualifications will be selected by the JAMS office in San Diego located at 401 B Street, San Diego, CA 92101 (after consultation with the parties). 

(d) The location of the mediation shall be in the County of San Diego, California. TSRI and Licensee hereby irrevocably submit to the
exclusive jurisdiction and venue of the mediator mutually selected by the parties or to the neutral mediator selected by JAMS of San Diego for purposes of the mediation, and to the exclusive jurisdiction and venue of the federal and state courts
located in San Diego County, California for any action or proceeding regarding this Agreement in the event mediation is unsuccessful as provided in sub-clause (e) below, or as provided in sub-clause (f) below, and waive any right to contest or otherwise object to such exclusive jurisdiction or venue, including without limitation any claim that such exclusive venue is not a convenient forum;
provided, however, that any Challenge that is subject to the exclusive jurisdiction of the U.S. Patent and Trademark Office and/or Board of Patent Appeals and Interferences shall be determined solely by U.S. Patent and Trademark Office and/or
Board of Patent Appeals and Interferences, as applicable; and provided, further, that any Challenge of any non-U.S. Licensed Patent Right shall be determined solely by a court or other government body
of competent jurisdiction. 
 (e) If the dispute is not resolved through mediation, either party may refer the dispute to a court of
competent jurisdiction in San Diego County, California. 
 (f) Notwithstanding anything to the contrary in this Agreement, prior to or
while a mediation proceeding is pending, either party has the right to seek and obtain injunctive and other equitable relief from a court of competent jurisdiction to enforce that party’s rights hereunder. 

14.9 Entire Agreement; Modification. This Agreement and all of the attached Exhibits (which are fully incorporated herein), together
with the RFOA, set forth the entire agreement and understanding between the parties as to the subject matter hereof and thereof, and supersede all prior or contemporaneous agreements or understandings, whether oral or written regarding such subject
matter. There shall be no amendments or modifications to this Agreement, except by a written document which is signed by both parties. 

  
 27 

 14.10 California Law. This Agreement shall be construed and enforced in accordance
with the laws of the State of California without regard to its conflicts or choice of laws principles thereof. 
 14.11 Headings. The
headings for each article and section in this Agreement have been inserted for convenience of reference only and are not intended to limit or expand on the meaning of the language contained in the particular article or section. 

14.12 Severability. Should any one or more of the provisions of this Agreement be held invalid or unenforceable by a court of competent
jurisdiction, it shall be considered severed from this Agreement and shall not serve to invalidate the remaining provisions thereof. The parties shall make a good faith effort to replace any invalid or unenforceable provision with a valid and
enforceable one such that the objectives contemplated by them when entering this Agreement may be realized. 
 14.13 No Waiver. Any
delay in enforcing a party’s rights under this Agreement or any waiver as to a particular default or other matter shall not constitute a waiver of such party’s rights to the future enforcement of its rights under this Agreement, excepting
only as to an express written and signed waiver as to a particular matter for a particular period of time. 
 14.14 Name. Whenever
there has been an assignment or a sublicense by Licensee as permitted by this Agreement, the term “Licensee” as used in this Agreement shall also include and refer to, if appropriate, such assignee or Sublicensee (to the extent of such
assignment or sublicense). 
 14.15 Attorney’s Fees. In the event of a dispute between the parties hereto or in the event of any
default hereunder, the party prevailing in the resolution of any such dispute or default shall be entitled to recover its reasonable attorney’s fees and other costs incurred in connection with resolving such dispute or default. TSRI and
Licensee each represent that it has been represented by its own counsel in the negotiation and execution of this Agreement. Each party further represents that it has relied solely on the advice and representation of its respective counsel in
agreeing to this Section 14.15 and all of the other provisions of this Agreement. 
 14.16 Notices. Any notices required by this
Agreement shall be in writing, shall specifically refer to this Agreement and shall be sent by registered or certified airmail, postage prepaid, or by telefax, telex or cable, charges prepaid, or by overnight courier, postage prepaid and shall be
forwarded to the respective addresses set forth below unless subsequently changed by written notice to the other party: 
  

			
	 For TSRI:
	  	The Scripps Research Institute
		  	10550 North Torrey Pines Road, TPC-9
		  	La Jolla, California 92037
		  	Attention: Director, Business Development
		  	Fax No.: 

  
 28 

			
		  	
	 with a copy to:
	  	The Scripps Research Institute
		  	10550 North Torrey Pines Road, TPC-8
		  	La Jolla, California 92037
		  	Attention: Business Counsel
		  	Fax No.: 
		
	 For Licensee:
	  	Vividion Therapeutics, Inc.
		  	230 Nassau Street
		  	Princeton, New Jersey 08540
		  	Attention: Chief Executive Officer
		  	Fax No.: 
		
	 with a copy to:
	  	Jon D. Grossman
		  	Dickstein Shapiro LLP
		  	1825 Eye Street NW
		  	Washington, DC 20006
		  	Fax No.: 

 Notices shall be deemed delivered upon the earlier of (a) when received; (b) three (3) days after it was sent by
registered or certified mail, return receipt requested; (c) the date notice is sent via facsimile, provided the receipt is verified and a hard copy is sent by one of the other manners set forth herein; or (d) the day immediately following
delivery to an overnight courier guaranteeing next-day delivery (except Sunday and holidays). 

14.17 Compliance with U.S. Laws. Nothing contained in this Agreement shall require or permit TSRI or Licensee to do any act
inconsistent with the requirements of any United States law, regulation or executive order as the same may be in effect from time to time. 

14.18 Counterparts. This Agreement may be executed in several counterparts that together shall constitute one and the same instrument.

  
 29 

 IN WITNESS WHEREOF, the parties have executed this Agreement by their duly authorized
representatives as of the date set forth above. 

 

			
	TSRI:
	
	THE SCRIPPS RESEARCH INSTITUTE
		
	By:	 	 /s/ Douglas Bingham

	Title:	 	COO

 

			
	LICENSEE:
	
	VIVIDION THERAPEUTICS, INC.
		
	By:	 	 /s/ John K. Clarke

	Title:	 	President

 
 

  
 30 

 EXHIBIT A 

LICENSED PATENT RIGHTS 

 EXHIBIT B 

TECHNICAL INFORMATION 

 EXHIBIT C 

REPORTING EVENTS 

 EXHIBIT D 

MILESTONES 

 Execution Version 

FIRST AMENDMENT TO LICENSE AGREEMENT 

This First Amendment to License Agreement (this “Amendment”) is made and entered into as of January 3, 2017, by and
between THE SCRIPPS RESEARCH INSTITUTE (“TSRI”), and VIVIDION THERAPEUTICS, INC. (“Licensee”). 

WHEREAS, TSRI and Licensee are parties to that certain License Agreement dated as of January 6, 2016 (the “License
Agreement”), covering certain patent rights of TSRI; and 
 WHEREAS, TSRI and Licensee wish to amend the License Agreement
as hereinafter set forth. 
 NOW THEREFORE, in consideration of the mutual covenants and conditions set forth herein, TSRI and
Licensee hereby agree as follows: 
 1. All capitalized terms utilized herein and not otherwise defined shall have the meanings ascribed to
them in the License Agreement. 
 2. Exhibit D to the License Agreement is hereby deleted in its entirety and replaced with the
following: 
 MILESTONES 
  

			
	 Milestone
	  	Time from
Effective Date
	 [***]
	  	[***]
	 [***]
	  	[***]
	 [***]
	  	[***]

 3. This Amendment may be executed in several counterparts, each of which will constitute an original instrument
and all of which will together constitute one and the same instrument. 
  

 4. Except to the extent modified herein, all of the terms, covenants and conditions of the
License Agreement shall remain in full force and effect and, as modified hereby, all of the terms and conditions of the License Agreement are hereby ratified and confirmed in all respects. 

5. This Amendment, together with the License Agreement, constitutes the entire agreement of the parties hereto with respect to the matters
stated herein and may not be amended or modified unless such amendment or modification shall be in writing and signed by the party against whom enforcement is sought. 

6. The terms, covenants and conditions contained in this Amendment shall bind and inure to the benefit of the parties hereto and their
respective successors and permitted assigns. 
 7. This Amendment will for all purposes be construed in accordance with and governed by the
laws of the State of California without regard to its conflict of laws rules that could result in the application of the laws of any other jurisdiction. 

[SIGNATURE PAGE FOLLOWS] 

  
 2 

 IN WITNESS WHEREOF, TSRI and Licensee have duly executed this Amendment as of the day
and year first above written. 
  

									
	TSRI:	 		 		 	LICENSEE:
			
	THE SCRIPPS RESEARCH INSTITUTE	 		 	VIVIDION THERAPEUTICS, INC.
					
	By:	 	 /s/ Matt Tremblay
	 		 	By:	 	 /s/ John K. Clarke

	Name:	 	Matt Tremblay	 		 	Name:	 	John K. Clarke
	Title:	 	VP, Business Development	 		 	Title:	 	President

 [Signature Page to First Amendment to License Agreement]EX-10.10

 Exhibit 10.10 

CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE VIVIDION THERAPEUTICS, INC. HAS DETERMINED THAT
IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT VIVIDION THERAPEUTICS, INC. TREATS AS PRIVATE OR CONFIDENTIAL. 
 RESEARCH FUNDING AND
OPTION AGREEMENT 
 by and between 

THE SCRIPPS RESEARCH INSTITUTE 
 a
California nonprofit 
 public benefit corporation 

and 
 Vividion Therapeutics, Inc.,

 a Delaware corporation 
  

 RESEARCH FUNDING AND OPTION AGREEMENT 

This Agreement is entered into this 15th day of September, 2014 (the “Effective
Date”), by and between THE SCRIPPS RESEARCH INSTITUTE, a California nonprofit public benefit corporation located at 10550 North Torrey Pines Road, La Jolla, California 92037 (“TSRI”), and VIVIDION THERAPEUTICS, INC., a Delaware
corporation located at C/O Cardinal Partners 230 Nassau Street Princeton NJ 08540 (“Sponsor”), with respect to the facts set forth below. 

RECITALS 
 A. TSRI is
engaged in fundamental scientific biomedical and biochemical research including research relating to accelerated drug discovery using chemical proteomics, as more particularly described herein. 

B. Sponsor is engaged in research and development aimed at discovery of therapeutically useful compounds. 

C. Sponsor desires to provide certain funding as part of TSRI’s research activities described above. 

D. Subject to any non-exclusive rights of the U.S. Government, TSRI is willing to grant to Sponsor an
option to acquire rights and licenses to certain intellectual property arising from the Research Program. 
 E. TSRI and Sponsor are in
discussions regarding a license agreement (the “Exclusive License Agreement”), pursuant to which TSRI would grant Sponsor an exclusive license under certain technology, materials and other information existing on the Effective Date and
relating to various technologies, including TSRI’s patent and other intellectual property rights therein (collectively, the “Existing Technology”). 

AGREEMENT 
 NOW,
THEREFORE, in consideration of the mutual covenants and conditions outlined herein, TSRI and Sponsor hereby agree as follows: 
 1.
DEFINITIONS. 
 1.1 Affiliate. The term “Affiliate” shall mean any entity which directly or indirectly controls, or
is controlled by Sponsor. The term “control” as used herein means (a) in the case of corporate entities, direct or indirect ownership of at least fifty percent (50%) of the stock or shares entitled to vote for the election of
directors; or (b) in the case of non-corporate entities, direct or indirect ownership of at least fifty percent (50%) of the equity interest with the power to direct the management and policies of such non-corporate entities. Unless otherwise specified, the term Sponsor includes Affiliates. 
 1.2
Agreement Number. This Agreement is TSRI number SFP-0000. 

  
 1 

 1.3 Biological Materials. The term “Biological Materials” shall mean any
Technology in the form of tangible materials together with any progeny, mutants, or derivatives thereof developed in performance of the Research Program. 

1.4 Confidential Information. The term “Confidential Information” shall mean any and all proprietary information of TSRI or
Sponsor which may be disclosed or made available by such party (the “disclosing party”) to the other party (the “receiving party”) at any time and from time to time during the term hereof. The fact that a disclosing party may
have marked or identified as confidential or proprietary any specific information shall be indicative that such disclosing party believes such information to be confidential or proprietary, but the failure to so mark information shall not
conclusively determine that such information was or was not considered confidential information by such disclosing party. Confidential Information shall also include any information which, given the circumstances surrounding the disclosure, would be
considered confidential by the disclosing party. Information shall not be considered confidential to the extent that the receiving party can demonstrate by competent proof that such information: 

(a) Is in the public domain at the time of disclosure to the receiving party; or 

(b) After disclosure to the receiving party, becomes part of the public domain, by publication or otherwise, without any breach of this
Agreement by the receiving party; or 
 (c) Was known to the receiving party prior to the Effective Date, which knowledge was acquired
independently and not from the disclosing party (including the disclosing party’s employees); or 
 (d) Is subsequently disclosed to
the receiving party in good faith by a third party who has a right to make such disclosure. 
 If Confidential Information is required to be
disclosed by law or court order, the Party required to make such disclosure shall limit the same to the minimum required to comply with the law or court order, and shall use reasonable efforts to attempt to seek confidential treatment for that
disclosure, and prior to making such disclosure that Party shall notify the other party, not later than ten (10) days (or such shorter period of time as may be reasonably practicable under the circumstances) before the disclosure in order to
allow that other Party to comment and/or to obtain a protective or other order, including extensions of time and the like, with respect to such disclosure. 

1.5 Field. The term “Field” shall mean [***]. 

1.6 Joint Technology. The term “Joint Technology” shall mean any Technology made or developed jointly by at least one
employee or consultant of Sponsor (it being understood that, for purposes of this paragraph, no TSRI employee shall be considered a consultant of Sponsor) and at least one employee of TSRI, as determined under principles of inventorship under US
patent law. 

  
 2 

 1.7 Patent Rights. The term “Patent Rights” shall mean (a) the U.S.
patent application(s) directed to the Technology; (b) the foreign counterpart applications of the respective application(s) referenced in sub-clause (a) above; (c) divisionals, substitutions (only
those claims of such substitutions that cover the identical subject matter that is covered by the application for which it is substituted), and continuations of any applications referenced in sub-clauses
(a) and (b) above; (d) any claim(s) of a continuation-in-part application of any application set forth in sub-clauses
(a)-(c) above that covers the exact subject matter disclosed in the specification of the respective application(s) referenced in sub-clause (a) above; (e) the patents issued from the applications
referenced in sub-clauses (a)-(c) above and any reissues, reexaminations, renewals and patent term extensions of such patents; and (f) any claim(s) of a patent issued from a
continuation-in-part application referenced in sub-clause (d) above that satisfies all of the requirements of sub-clause (d), and any claim(s) of a reissue, reexamination, renewal and patent term extension of a patent issued from a
continuation-in-part application referenced in sub-clause (d) that satisfies all of the requirements of sub-clause (d); provided, however, that in all cases under sub-clauses (b) – (f) above, the Patent Rights include only the subject matter and claims
contained in the items referenced in sub-clauses (b) – (f) that are entitled to the priority date of the respective application(s) referenced in sub-clause
(a) above. 
 1.8 Principal Investigator. The term “Principal Investigator” shall mean Dr. Cravatt, together
with such replacement persons selected in accordance with the provisions of Section 2.2 hereof. 
 1.9 Research Program. The
term “Research Program” shall mean the research program to be undertaken by TSRI under the direction and control of the Principal Investigator as expressly set forth on Exhibit A hereto. 

1.10 Research Tool. The term “Research Tool” shall mean any Technology which is designed or utilized for basic research
purposes or internal drug discovery purposes and which is not utilized to produce, or incorporated into, a product. 
 1.11
Technology. The term “Technology” shall mean any invention, discovery, know-how, Biological Material, software, information and data, whether patentable or not, conceived and reduced to
practice during the performance of the Research Program. 
 1.12 TSRI Technology. The term “TSRI Technology” shall mean
any Technology, made or developed solely by one or more employees of TSRI, as determined under principles of inventorship under the patent laws of the United States of America. 

2. CONDUCT OF RESEARCH PROGRAM. 

2.1 Conduct of Research Program. TSRI hereby agrees to use reasonable efforts to perform the Research Program subject to the
provisions of this Agreement. Notwithstanding the foregoing, TSRI makes no warranties or representations regarding its ability to achieve, nor shall it be bound to accomplish, any particular research objective or results. 

2.2 Supervision of Research Program. TSRI agrees that the Research Program at TSRI shall be conducted by or under the direct
supervision of the Principal Investigator. In the event that the Principal Investigator leaves TSRI, or terminates his/her 

  
 3 

 involvement in the Research Program, TSRI shall use its best efforts to find a replacement Principal
Investigator acceptable to Sponsor, which acceptance shall not be unreasonably withheld. In the event that TSRI shall fail to appoint a replacement Principal Investigator reasonably acceptable to Sponsor, Sponsor shall have a right to terminate this
Agreement upon delivery to TSRI of written notice of termination pursuant to this Section 2.2, which notice must be delivered to TSRI not more than [***] days after delivery by TSRI to Sponsor of the name of the replacement Principal
Investigator. 
 2.3 Reports. TSRI and the Principal Investigator shall keep complete and accurate records of the results of the
Research Program. TSRI agrees to provide oral reports on a [***] basis, and Sponsor shall have the right, upon reasonable request from time to time, to discuss with TSRI, the Principal Investigator and other appropriate TSRI personnel, in person or
otherwise, the Research Program and the results thereof. TSRI agrees that within [***] days following [***] during the term of this Agreement, TSRI shall furnish Sponsor with a written report summarizing the results of the research included within
the scope of the Research Program conducted by TSRI, during the immediately preceding calendar year, including but not limited to all data, conclusions, results, observations and a detailed description of all procedures. Subject to Section 3.1,
all such reports shall be treated as Confidential Information by Sponsor. In the event that Sponsor identifies any Technology disclosed in such report as to which it would like to exercise its option and which has not been previously disclosed to
Sponsor by TSRI in accordance with Section 3.2, Sponsor shall notify TSRI of such Technology in writing. Promptly following such notification, TSRI shall provide Sponsor with a Technology Disclosure in accordance with Section 3.2. 

2.4 Financial and Staffing Obligations 

(a) Contributions of Parties to Research Program. Contributions in the form of financial support, equipment, personnel, technology and
other necessary components for the conduct of the Research Program shall be made by the parties in accordance with the terms set forth on Exhibit B. All payments due to TSRI by Sponsor shall be payable in U.S. Dollars in [***] in advance and due
within [***] days of each respective payment date. The first payment for the period starting on the Effective Date and continuing through March 31, 2015 shall be $[***] US Dollars. The amounts specified above include all expense, overhead and
other related costs due by Sponsor to TSRI in connection with the Research Program, and no other amounts shall be due or payable by Sponsor to TSRI or the Principal Investigator for performance of the Research Program. Each payment must reference
the Research Project title, Agreement Number and Principal Investigator for purposes of identification. Payments under this Section 2.4(a) shall be sent to: 

 

			
	                                    	  	 The Scripps Research Institute
 10550 North
Torrey Pines Road, TPC-7
 La Jolla, California 92037

Attn: Vice President, Sponsored Programs
 Fax
No.:

  
 4 

			
	With a copy to:	  	 The Scripps Research Institute
 10550 North
Torrey Pines Road, TPC-9
 La Jolla, California 92037

Attn: Director, Technology Development
 Fax No.:

		
	Or if payment is by wire transfer:	  	 Bank of America
 Account Number:

ABA Routing Number:
 Attn: Kathy McDowell

Bank of America
 San Diego Corporate Banking

450 B Street, Suite 100
 San Diego, California 92101

 TSRI shall not be obligated to perform any of the research specified herein or to take any other action required under this
Agreement if the funding is not provided as set forth in Exhibit B and in accordance with the payment schedule as set forth in this Section 2.4(a). Furthermore, should Sponsor fail to make the first payment to TSRI in accordance with this
Section 2.4(a), TSRI shall have the right to immediately terminate this Agreement and this Agreement shall be null and void ab initio. 

(b) Capital Equipment. Equipment purchased by TSRI with funds provided by Sponsor shall be the property of TSRI. All capital equipment
provided under this Agreement by Sponsor for the use of TSRI remains the property of the Sponsor unless other disposition is mutually agreed upon in writing by the Parties. If title to this equipment remains with the Sponsor, Sponsor is responsible
for maintenance and repair of the equipment, insuring the equipment against damage or loss, and the costs of its transportation to and from the site where it will be used. 

(c) Indirect Cost Adjustment. TSRI shall have the right to adjust the payment amounts referenced above to reflect changes in the
indirect cost rate negotiated between TSRI and the U.S. Government and that will be in effect during the quarter that the work is performed. TSRI will notify Sponsor in writing of any change in the indirect cost rate before the effective date of
such change. The corresponding direct costs will remain fixed as specified in Exhibit B. 
 3. OPTION FOR LICENSE. 

3.1 Grant of Option. Subject to the terms of this Agreement and the reservation of rights specified in Sections 4.2 and 4.3, TSRI
hereby grants to Sponsor: 

  
 5 

 (a) an exclusive option (the “Option”) to acquire an exclusive, worldwide
license, under the terms and conditions of the Exclusive License Agreement, under TSRI’s rights in the Patent Rights, to make, have made, use, offer for sale, sell, have sold and import products, processes and Biological Material in the Field.
In the event that a product, process or Biological Material utilizes a Research Tool, such Research Tool shall be made available to Sponsor solely on a non-exclusive basis. 

(b) a non-exclusive, royalty-free, non-transferable license
to make and use Technology solely for Sponsor’s internal research purposes during the performance of the Research Program. Any transfer of materials to Sponsor under this Section 3.1(b) shall require the execution of a Material Transfer
Agreement. The terms of such Material Transfer Agreement shall be materially consistent with the form Material Transfer Agreement attached hereto as Exhibit C. 

3.2 Disclosure of Technology. After Principal Investigator submits an invention disclosure covering any Technology to TSRI’s
Office of Technology Development, TSRI shall disclose such Technology in writing to Sponsor (the “Technology Disclosure”). TSRI shall use [***] to provide a Technology Disclosure that contains sufficient detail to (i) [***]; and (ii)
[***]. All such Technology Disclosures shall be maintained in confidence by Sponsor. 
 3.3 Option. Sponsor shall have a period of
[***] days from receipt of the Technology Disclosure from TSRI (“Option Period”), within which to exercise its Option with respect to the particular Technology disclosed therein. 

3.4 Exercise of Option. Sponsor shall exercise its Option by delivering to TSRI a written notice within the Option Period which
specifies the particular Technology for which the Option is being exercised. Upon such notification, Sponsor and TSRI shall prepare and execute an amendment that adds the Technology to the Exclusive License Agreement [***] and certain other terms as
may be mutually agreed by the Parties. 
 3.5 Patent Filings. [***] shall direct and control the preparation, filing and prosecution
of patent applications and patents within the Patent Rights. [***] shall pay all fees and costs incurred during the term of this Agreement (including any subsequent Option Period) associated with work performed by TSRI’s Office of Patent
Counsel and any independent counsel and related to the preparation, filing, prosecution and maintenance of the Patent Rights. Payment shall be made within [***] days after [***] receives an invoice therefor. Failure of [***] to pay patent fees and
expenses as set forth above shall immediately relieve [***] from its obligation to incur any further patent fees and expenses. [***]’s obligation to pay all patent fees and costs incurred pursuant to this Agreement shall survive the termination
or expiration of this Agreement. Both parties hereto agree that [***] may, at its sole discretion, utilize TSRI’s Office of Patent Counsel in lieu of or in addition to independent counsel for patent prosecution and maintenance of patent
application(s). [***] shall have full rights of consultation with the patent attorney so selected on all matters relating to patent application(s). 

  
 6 

 3.6 Joint Technology. The parties hereby agree that in the event that the disclosed
Technology is Joint Technology and that Sponsor does not exercise its Option to include the Technology in the Exclusive License Agreement subject to Section 3.4, both Parties shall (i) have no further obligations to each other with respect
to such Joint Technology and any resulting Patent Rights; and (ii) be free to independently license or otherwise dispose of their rights to such Joint Technology and any resulting Patent Rights on a worldwide basis without accounting to the
other Party. 
 4. INTERESTS AND RIGHTS IN INTELLECTUAL PROPERTY. 

4.1 Title. TSRI shall retain sole ownership and title to TSRI Technology and to all intellectual property rights related thereto. TSRI
shall, in the good faith exercise of its discretion, undertake reasonable efforts to preserve and maintain its ownership and title as TSRI deems appropriate. Ownership of and title to Joint Technology shall be vested jointly in TSRI and Sponsor,
with each owning an undivided interest therein. Ownership of Patent Rights shall follow inventorship under principles arising under U.S. patent law. 

4.2 Governmental Interest. TSRI and Sponsor acknowledge that TSRI has received, and expects to continue to receive, funding from the
United States Government in support of TSRI’s research activities. TSRI and Sponsor acknowledge and agree that their respective rights and obligations pursuant to this Agreement shall be subject to the rights of the United States Government,
existing and as amended, which may arise or result from TSRI’s receipt of research support from the United States Government, including but not limited to, 37 CFR 401, the NIH Grants Policy Statement and the NIH Guidelines for Obtaining and
Disseminating Biomedical Research Resources. 
 4.3 Reservation of Rights. TSRI reserves the right to use for any internal research
or educational purposes any Patent Rights, Biological Materials, or Research Tools, without TSRI being obligated to pay Sponsor any royalties or other compensation. In addition, TSRI reserves the right to grant
non-exclusive, non-commercial research and educational use licenses to other nonprofit or academic institutions to Patent Rights, Biological Materials, or Research
Tools, without the other non-profit entity being obligated to pay Sponsor any royalties or other compensation. TSRI shall have no obligation to notify or inform Sponsor of such use or licenses. 

5. CONFIDENTIALITY AND PUBLICATION. 

5.1 Treatment of Confidential Information. The parties agree that during the term of this Agreement, and for a period of [***] years after
termination or expiration of this Agreement, the receiving party will (a) maintain in confidence all Confidential Information to the same extent such party maintains its own proprietary information; (b) not disclose such Confidential
Information to any third party without the prior written consent of the disclosing party; and (c) not use such Confidential Information for any purpose except those permitted by this Agreement (and, if and to the extent applicable, the
Exclusive License Agreement). 

  
 7 

 5.2 Publications. Sponsor acknowledges that it is the general policy of TSRI to
encourage publication of research results in technical or scientific journals; and Sponsor agrees that TSRI shall have a right to publish in accordance with its general policy. TSRI shall submit to Sponsor copies of proposed publications which
describe Technology and afford Sponsor a period of [***] days to review the publication to (i) ascertain whether Sponsor’s Confidential Information would be disclosed by the publication; and (ii) ascertain whether or not submission or
presentation of the publication would preclude the parties from obtaining patent rights claiming Technology disclosed therein unless an application is filed with relevant patent authorities. If such publication discloses Sponsor’s Confidential
Information and upon Sponsor’s written request, TSRI shall remove such Confidential Information or delay publication for up to an additional [***] days to allow Sponsor to protect its Confidential Information by filing a patent application(s).
In the event that Sponsor identifies any potentially patentable Technology with respect to which it wishes to file, or have TSRI file (as applicable), patent application(s), Sponsor shall notify TSRI of such in writing. Upon such notification, TSRI
shall, at its option, either delete the enabling portion of the proposed publication or presentation, or withhold publication or delay presentation for up to an additional [***] days to allow filing of patent application(s). Absent receipt by TSRI
of any written instruction by Sponsor within the [***] day period, TSRI shall be free to publish the proposed publication. 
 5.3
Publicity. Except as otherwise provided herein or required by law, no party shall originate any publication, news release or other public announcement, written or oral, whether in the public press, stockholders’ reports, or otherwise,
relating to this Agreement or to the performance hereunder without the prior written approval of the other party, which approval shall not be unreasonably withheld. Scientific publications published in accordance with Section 5.2 of this
Agreement shall not be construed as publicity governed by this Section 5.3. 
 6. WARRANTIES. 

6.1 Limited Warranty. TSRI hereby represents and warrants that it has full right and power to enter into this Agreement. TSRI MAKES NO
OTHER WARRANTIES CONCERNING PATENT RIGHTS, TECHNOLOGY, RESEARCH TOOLS, BIOLOGICAL MATERIALS OR ANY OTHER MATTER WHATSOEVER, INCLUDING WITHOUT LIMITATION, ANY EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NON-INFRINGEMENT OF THIRD PARTY RIGHTS OR ARISING OUT OF COURSE OF CONDUCT OR TRADE CUSTOM OR USAGE, AND TSRI DISCLAIMS ALL SUCH EXPRESS OR IMPLIED WARRANTIES. TSRI MAKES NO WARRANTY OR REPRESENTATION AS TO THE
VALIDITY OR SCOPE OF PATENT RIGHTS, OR THAT ANY PRODUCT, PROCESS, SERVICE, BIOLOGICAL MATERIAL, OR RESEARCH TOOL WILL BE FREE FROM AN INFRINGEMENT ON PATENTS OR OTHER INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES, OR THAT NO THIRD PARTIES ARE IN ANY
WAY INFRINGING UPON ANY PATENT RIGHTS, TECHNOLOGY, RESEARCH TOOLS OR BIOLOGICAL MATERIALS COVERED BY THIS AGREEMENT. FURTHER, TSRI HAS MADE NO INVESTIGATION AND MAKES NO REPRESENTATION THAT THE PATENT RIGHTS, RESEARCH TOOLS OR BIOLOGICAL
MATERIALS ARE SUITABLE FOR SPONSOR’S PURPOSES. 

  
 8 

 IN NO EVENT SHALL [***] BE LIABLE TO THE OTHER PARTY FOR ANY INDIRECT, SPECIAL, INCIDENTAL, EXEMPLARY OR
CONSEQUENTIAL DAMAGES (INCLUDING, WITHOUT LIMITATION, DAMAGES FOR LOSS OF PROFITS OR EXPECTED SAVINGS OR OTHER ECONOMIC LOSSES, OR FOR INJURY TO PERSONS OR PROPERTY) ARISING OUT OF OR IN CONNECTION WITH THIS AGREEMENT OR ITS SUBJECT MATTER.
TSRI’S AGGREGATE LIABILITY, IF ANY, FOR ALL DAMAGES OF ANY KIND RELATING TO THIS AGREEMENT OR ITS SUBJECT MATTER SHALL NOT EXCEED THE AMOUNT PAID BY SPONSOR TO TSRI UNDER THIS AGREEMENT. THE FOREGOING EXCLUSIONS AND LIMITATIONS SHALL APPLY TO
ALL CLAIMS AND ACTIONS OF ANY KIND AND ON ANY THEORY OF LIABILITY, WHETHER BASED ON CONTRACT, TORT (INCLUDING, BUT NOT LIMITED TO NEGLIGENCE OR STRICT LIABILITY), OR ANY OTHER GROUNDS, AND REGARDLESS OF WHETHER A PARTY HAS BEEN ADVISED OF THE
POSSIBILITY OF SUCH DAMAGES, AND NOTWITHSTANDING ANY FAILURE OF ESSENTIAL PURPOSE OF ANY LIMITED REMEDY. THE PARTIES FURTHER AGREE THAT EACH WARRANTY DISCLAIMER, EXCLUSION OF DAMAGES OR OTHER LIMITATION OF LIABILITY HEREIN IS INTENDED TO BE
SEVERABLE AND INDEPENDENT OF THE OTHER PROVISIONS SINCE THEY EACH REPRESENT SEPARATE ELEMENTS OF RISK ALLOCATION BETWEEN THE PARTIES. 
 7.
TERM AND TERMINATION. 
 7.1 Term. Unless terminated sooner, the initial term of this Agreement shall commence on the
Effective Date and shall continue until the earlier of (a) August 31, 2017, and (b) the completion of the Research Program. 

7.2 Termination by Sponsor. Sponsor may terminate this Agreement by giving thirty (30) days advance written notice of termination
to TSRI. 
 7.3 Termination Upon Default. Except as specified in Section 7.4, the failure of a party to perform any obligation
required of it to be performed hereunder and the failure to cure within sixty (60) days (or, in the case of any failure by Sponsor to make any payment hereunder when due, within thirty (30) days) after receipt of notice from the other
party specifying in reasonable detail the nature of such default, shall constitute an event of default hereunder. Upon the occurrence of an event of default that is not cured within the applicable notice period, the
non-defaulting party may deliver to the defaulting party written notice of intent to terminate, such termination to be effective upon the date set forth in such notice. Such termination rights shall be in
addition to and not in substitution for any other remedies that may be available to the non-defaulting party serving such notice against the defaulting party. Termination pursuant to this Section 7.3
shall not relieve the defaulting party of liability and damages to the non-defaulting party for breach of this Agreement. Waiver by any party of a single default or a succession of defaults shall not deprive
such party of any right to terminate this Agreement arising by reason of any subsequent default. 
 7.4 Termination Upon Insolvency.
This Agreement may be terminated by a party upon written notice of termination to the other party (“Insolvent Party”) in the event of the filing of bankruptcy by the Insolvent Party, or the appointment of a receiver of any of the 

  
 9 

 Insolvent Party’s assets, or the making by the Insolvent Party of any assignment for the benefit of
creditors, or the institution of any involuntary bankruptcy proceedings against the Insolvent Party under any bankruptcy law that are not dismissed within sixty (60) days after institution. Termination shall be effective upon the date specified
in this notice. 
 7.5 Effect of Expiration or Termination. 

(a) Termination Upon Default of Sponsor. Upon the termination of this Agreement by reason of a default by Sponsor, neither party shall
have any further rights or obligations with respect to this Agreement, other than the rights and obligations of the parties that accrued prior to the effective date of such termination (including, without limitation, the obligation of Sponsor to
make any and all final payments accrued prior to the date of termination and the obligation of the parties to make all reports required hereunder), and except as provided below. Upon such termination of this Agreement, the parties shall continue to
abide by their non-disclosure obligations as described in Section 5.1 and each party hereto shall fulfill any other obligations incurred prior to such termination. Any such termination of this Agreement
shall not constitute the termination of any license or any other agreements between the parties which are then in effect (such as, but not limited to, the Exclusive License Agreement) except as expressly provided therein. In addition, upon such
termination, Sponsor’s Option under Section 3.1 shall be deemed automatically cancelled, and Sections 4, 6, 7, 8 and 9 shall survive any such termination. 

(b) Expiration or Termination upon Default of TSRI. Upon the expiration of this Agreement at its regularly scheduled expiration date,
or upon a termination of this Agreement on account of a default by TSRI, then TSRI shall make the disclosures required by Section 3.2 for Technology conceived or reduced to practice up to the date of said expiration or termination; Sponsor
shall have the right to exercise its option with respect to said Technology in accordance with the schedule and procedures specified in Sections 3.3 and 3.4 above; and any non-exclusive licenses that have been
granted under Section 3.1 shall survive. Additionally, each party shall perform all other obligations up to the date of said expiration or termination; the parties shall continue to abide by their
non-disclosure obligations described in Section 5.1; and any previously existing license agreements or other agreements between the parties (such as, but not limited to, the Exclusive License Agreement)
shall continue in effect. No such expiration or termination of this Agreement shall affect the rights and obligations of the parties that accrued prior to the effective date of such expiration or termination. In addition, upon such expiration or
termination, Sections 4, 6, 7, 8 and 9 shall survive. 
 8. ASSIGNMENT; SUCCESSORS. 

8.1 Assignment. Any and all assignments of this Agreement or any rights granted hereunder by Sponsor are void except to an Affiliate
of Sponsor, without the prior written consent of TSRI. 
 8.2 Binding Upon Successors and Assigns. Any and all assignments of this
Agreement or any rights granted hereunder by Sponsor without the prior written consent of TSRI are void, except that, without the prior written consent of TSRI, (a) Sponsor may assign this Agreement and its rights and obligations hereunder to
an Affiliate of Sponsor; and 

  
 10 

 (b) Sponsor may assign this Agreement and its rights and obligations hereunder in connection with the
transfer or sale of all or substantially all of Sponsor’s business or assets to a third party, whether by merger, sale of stock, sale of assets or otherwise, subject to Section 8.2 hereof. 

9. GENERAL PROVISIONS. 

9.1 Independent Contractors. The relationship between TSRI and Sponsor is that of independent contractors. TSRI and Sponsor are not
joint venturers, partners, principal and agent, master and servant, employer or employee, and have no other relationship other than independent contracting parties. TSRI and Sponsor shall have no power to bind or obligate each other in any manner,
other than as is expressly set forth in this Agreement. 
 9.2 Arbitration. Any controversy or claim arising out of or relating to
this Agreement, or the breach thereof, shall be settled by binding confidential arbitration in accordance with the Commercial Arbitration Rules of the American Arbitration Association (“AAA”), and the procedures set forth below. In the
event of any inconsistency between the Rules of AAA and the procedures set forth below, the procedures set forth below shall control. Judgment upon the award rendered by the arbitrators may be enforced in any court having jurisdiction thereof. 

(a) Location. The location of the arbitration shall be in the County of San Diego. TSRI and Sponsor hereby irrevocably submit to the
exclusive jurisdiction and venue of the American Arbitration Association arbitration panel selected by the parties and located in San Diego County, California for any dispute regarding this Agreement, and to the exclusive jurisdiction and venue of
the federal and state courts located in San Diego County, California for any action or proceeding to enforce an arbitration award or as otherwise provided in Section 9.2(e) below, and waive any right to contest or otherwise object to such
jurisdiction or venue. 
 (b) Selection of Arbitrators. The arbitration shall be conducted by a panel of three neutral arbitrators
who are independent and disinterested with respect to the parties, this Agreement, and the outcome of the arbitration. Each party shall appoint one neutral arbitrator, and these two arbitrators so selected by the parties shall then select the third
arbitrator, and all arbitrators must have at least ten (10) years experience in mediating or arbitrating cases regarding the same or substantially similar subject matter as the dispute between TSRI and Sponsor. If one party has given written
notice to the other party as to the identity of the arbitrator appointed by the party, and the party thereafter makes a written demand on the other party to appoint its designated arbitrator within the next ten days, and the other party fails to
appoint its designated arbitrator within ten days after receiving said written demand, then the arbitrator who has already been designated shall appoint the other two arbitrators. 

(c) Discovery. The arbitrators shall decide any disputes and shall control the process concerning these
pre-hearing discovery matters. Pursuant to the Rules of AAA, the parties may subpoena witnesses and documents for presentation at the hearing. 

(d) Case Management. Prompt resolution of any dispute is important to both parties; and the parties agree that the arbitration of any
dispute shall be 

  
 11 

 conducted expeditiously. The arbitrators are instructed and directed to assume case management initiative
and control over the arbitration process (including scheduling of events, pre-hearing discovery and activities, and the conduct of the hearing), in order to complete the arbitration as expeditiously as is
reasonably practical for obtaining a just resolution of the dispute. 
 (e) Remedies. The arbitrators may grant any legal or
equitable remedy or relief that the arbitrators deem just and equitable, to the same extent that remedies or relief could be granted by a state or federal court, provided however, that no punitive damages may be awarded. No court action shall be
maintained seeking punitive damages. The decision of any two of the three arbitrators appointed shall be binding upon the parties. Notwithstanding anything to the contrary in this Agreement, prior to or while an arbitration proceeding is pending,
either party has the right to seek and obtain injunctive and other equitable relief from a court of competent jurisdiction to enforce that party’s rights hereunder. In addition, no claim, dispute or controversy that concerns the validity,
enforceability, scope or infringement of a patent, trademark or copyright shall be subject to arbitration or any other provision of this Section 9.2. 

(f) Expenses. The expenses of the arbitration, including the arbitrators’ fees, expert witness fees, and attorney’s fees,
may be awarded to the prevailing party, in the discretion of the arbitrators, or may be apportioned between the parties in any manner deemed appropriate by the arbitrators. Unless and until the arbitrators decide that one party is to pay for all (or
a share) of such expenses, both parties shall share equally in the payment of the arbitrators’ fees as and when billed by the arbitrators. 

(g) Confidentiality. Except as set forth below and as necessary to obtain or enforce a judgment upon any arbitration award, the
parties shall keep confidential the fact of the arbitration, the dispute being arbitrated, and the decision of the arbitrators. Notwithstanding the foregoing, the parties may disclose information about the arbitration to persons who have a need to
know, such as directors, trustees, management employees, witnesses, experts, investors, attorneys, lenders, insurers, and others who may be directly affected. Additionally, if a party has stock which is publicly traded, the party may make such
disclosures as are required by applicable securities laws, but will use commercially reasonably efforts to seek confidential treatment for such disclosure. 

9.3 Entire Agreement; Modification. This Agreement and all of the attached Exhibits set forth the entire agreement and understanding
between the parties as to the subject matter hereof, and supersede all prior or contemporaneous written or oral agreements. There shall be no amendments or modifications to this Agreement, except by a written document which is signed by both
parties. 
 9.4 California Law. This Agreement shall be construed and enforced in accordance with the laws of the State of
California notwithstanding any conflicts or choice of laws provisions. 
 9.5 No Use of Name. The use of the name “The Scripps
Research Institute”, “Scripps”, “TSRI” or any variation thereof in connection with the advertising, sale or performance of products, processes, services, Biological Materials or Research Tools is expressly prohibited. 

  
 12 

 9.6 Headings. The headings for each article and section in this Agreement have been
inserted for the convenience of reference only and are not intended to limit or expand on the meaning of the language contained in the particular article or section. 

9.7 Severability. Should any one or more of the provisions of this Agreement be held invalid or unenforceable by a court of competent
jurisdiction, it shall be considered severed from this Agreement and shall not serve to invalidate the remaining provisions thereof. The parties shall make a good faith effort to replace any invalid or unenforceable provision with a valid and
enforceable one such that the objectives contemplated by them when entering this Agreement may be realized. 
 9.8 No Waiver. Any
delay in enforcing a party’s rights under this Agreement or any waiver as to a particular default or other matter shall not constitute a waiver of such party’s rights to the future enforcement of its rights under this Agreement, excepting
only as to an express written and signed waiver as to a particular matter for a particular period of time. 
 9.9 Notices. Any
notices required by this Agreement shall be in writing, shall specifically refer to this Agreement and shall be sent by registered or certified airmail, postage prepaid, or by telefax, telex or cable, charges prepaid, or by overnight courier,
postage prepaid, and shall be forwarded to the respective addresses set forth below unless subsequently changed by written notice to the other party: 
  

			
	FOR TSRI:	  	The Scripps Research Institute
		  	10550 North Torrey Pines Road, TPC-9
		  	La Jolla, California 92037
		  	Attn: Director, Technology Development
		  	Fax No.:
		
	With a copy to:	  	The Scripps Research Institute
		  	10550 North Torrey Pines Road, TPC-8
		  	La Jolla, California 92037
		  	Attention: Chief Business Counsel
		  	Fax No.:
		
	FOR SPONSOR:	  	Vividion Therapeutics, Inc.
		  	Attn: Chief Executive Officer
		  	C/O Cardinal Partners 230 Nassau Street Princeton NJ 08540

 Notices shall be deemed delivered upon the earlier of (i) when received; (ii) three (3) days after deposit
into the U.S. mail; (iii) the date notice is sent via telefax, telex or cable; or (iv) the day immediately following delivery to an overnight courier guaranteeing next-day delivery (except Sunday and
holidays). 
 9.10 Compliance with U.S. Laws. Nothing contained in this Agreement shall require or permit TSRI or Sponsor to do any
act inconsistent with the requirements of any United States law, regulation or executive order as the same may be in effect from time to time. 

  
 13 

 9.11 Indemnity. Sponsor shall indemnify, defend (by counsel reasonably acceptable to
TSRI) and hold harmless TSRI and any parent, subsidiary or other affiliated entity of TSRI and their trustees, directors, officers, employees, scientists, agents, successors, assigns and other representatives (collectively, the
“Indemnitees”) from and against all claims, suits, actions, damages, liabilities, losses and other expenses, including without limitation reasonable attorney’s fees, expert witness fees and costs incurred by or asserted against the
Indemnitees, whether or not a lawsuit or other proceeding is filed (collectively “Claim”), that arise out of or relate to any third party allegations or suits regarding Sponsor’s use of the Technology or the exercise of its non-exclusive license rights under Section 3.1(b). Sponsor shall not enter into any settlement of such Claims that imposes any obligation on TSRI, that does not unconditionally release TSRI from all liability
or that would have an adverse effect on TSRI’s reputation or business without TSRI’s prior written consent. In the event an Indemnitee seeks indemnification with respect to a Claim under this Section 9.11, it shall notify Sponsor in
writing of such Claim as soon as reasonably practicable after it receives notice of such Claim, shall permit Sponsor to assume direction and control of the defense of the Claim (including the right to settle the Claim solely for monetary
consideration, subject to the limitations of the preceding sentence) using counsel selected by Sponsor and reasonably acceptable to TSRI, and shall cooperate as reasonably requested (at the expense of Sponsor) in the defense of the Claim.
Notwithstanding the above, Indemnitees, at [***] expense, shall have the right to retain separate independent counsel to assist in defending any such Claims. In the event Sponsor fails to promptly indemnify and defend such Claims and/or pay
Indemnitees’ expenses as provided above, Indemnitees shall have the right to defend themselves, and in that case, Sponsor shall reimburse Indemnitees for all of their reasonable attorney’s fees, costs and damages incurred in settling or
defending such Claims within [***] days of each of Indemnitees’ written requests. This indemnity shall be a direct payment obligation and not merely a reimbursement obligation of Sponsor to Indemnitees. 

IN WITNESS WHEREOF, the parties have executed this Agreement by their duly authorized representatives as of the date set forth above. 

 

									
	TSRI:	  		 	SPONSOR:
			
	THE SCRIPPS RESEARCH INSTITUTE	  		 	VIVIDION THERAPEUTICS
					
	By:	 	 /s/ Scott Forrest
	  	        	 	By:	 	 /s/ John K. Clarke

		 	Scott Forrest	  		 		 	John K. Clarke
	Title:	 	Business Development, VP	  		 	Title:	 	President

  
 14 

 EXHIBIT A 

RESEARCH PROGRAM 
 Vividion SFP –
Bullet-Point Objectives 
 [***] 

 EXHIBIT B 

Principal Investigator/Program Director (Last, First, Middle): Cravatt, Benjamin F. 

 EXHIBIT C 

FORM OF MATERIAL TRANSFER AGREEMENT 

THE SCRIPPS RESEARCH INSTITUTE 

 AMENDMENT TO RESEARCH FUNDING AND OPTION AGREEMENT 

This is an Amendment, dated as of December 13, 2016 (this “Amendment”) to the Research Funding and Option Agreement, dated
September 15, 2014 (the “Funding Agreement”), by and between THE SCRIPPS RESEARCH INSTITUTE, a California nonprofit public benefit corporation (“TSRI”), and VIVIDION THERAPEUTICS, INC., a Delaware corporation
(“Sponsor”). 
 RECITALS 

A. TSRI and Sponsor entered into the Funding Agreement and have been operating under the Funding Agreement since its effective date. 

B. TSRI and Sponsor have determined that it is in the best interest of both TSRI and Sponsor to amend the Funding Agreement as set forth in
this Amendment. 
 AGREEMENT 

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, TSRI and Sponsor hereby
agree as follows: 
 1. Amendment of Section 3.1 (a). Paragraph (a) of Section 3.1 of the Funding
Agreement is hereby amended by deleting the last sentence of such paragraph. 
 2. Continuation of Funding Agreement. In all other
respects the Funding Agreement remains in full force and effect as originally executed. 
 IN WITNESS WHEREOF, the parties have executed
this Agreement by their duly authorized representatives as of the date set forth above. 
  

									
	TSRI:	 		 	LICENSEE:
			
	THE SCRIPPS RESEARCH INSTITUTE	 		 	VIVIDION THERAPEUTICS, INC.
					
	By:	 	 /s/ Eric Topol
	 		 	By:	 	 /s/ John K. Clarke

	Title:	 	 Vice President
	 		 	Title:	 	 President

 AMENDMENT NO.2 TO RESEARCH FUNDING AND OPTION AGREEMENT 

This is Amendment 2, dated as of February 15, 2017 (this “Amendment”) to the Research Funding and Option Agreement, dated
September 15, 2014, and as amended on December 13, 2016 (the “Funding Agreement”), by and between THE SCRIPPS RESEARCH INSTITUTE, a California nonprofit public benefit corporation (“TSRI”), and VIVIDION THERAPEUTICS,
INC., a Delaware corporation (“Sponsor”). 
 RECITALS 

A. TSRI and Sponsor entered into the Funding Agreement and have been operating under the Funding Agreement since its effective date. 

B. TSRI and Sponsor have determined that it is in the best interest of both TSRI and Sponsor to extend the term of the Funding Agreement and
amend the scope of the Research Program as set forth in this Amendment for additional funding. 
 AGREEMENT 

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, TSRI and Sponsor hereby
agree as follows: 
 1. The Funding Agreement is amended to include the attached Exhibit A-2,
which lists additional aims to the Research Program for the Funding Agreement. Exhibit A-2 is incorporated into and made part of the Funding Agreement. References to Exhibit A in Paragraph 1.9 of
the Funding Agreement are amended to also refer to Exhibit A-2. 
 2. The Funding Agreement is
amended to include the attached Exhibit B-2, which lists the applicable cost information for additional aims to the Research Program being added to the Funding Agreement. Exhibit B-2 is incorporated into and made part of the Agreement. References to Exhibit B in Paragraph 2.4 of the Funding Agreement are amended to also refer to Exhibit B-2.

 3. Section 2.4 of the Funding Agreement, entitled “Financial and Staffing Obligations” is hereby amended to include the
following after the sentence “The first payment for the period starting on the Effective Date and continuing through March 15, 2015 shall be $[***] US Dollars.”: 

For the period September 15, 2016 through February 14, 2017 the payment shall be [***]. For each of the six month periods beginning
February 15, 2017 and ending February 14, 2020 the payment shall be $[***]. 
 4. Section 7.2 Term. The date “August 31,
2017” shall be deleted and replaced with February 14, 2020. 
 5. Continuation of Funding Agreement. In all other respects
the Funding Agreement remains in full force and effect as originally executed. 

  
 1 

 IN WITNESS WHEREOF, the parties have executed this Agreement by their duly authorized
representatives as of the date set forth above. 
  

									
	 TSRI:
	  		  	SPONSOR:
			
	 THE SCRIPPS RESEARCH INSTITUTE
	  		  	V1VIDION THERAPEUTICS, INC.
					
	 By:
	  	 /s/ Matt Tremblay
	  		  	 By:
	  	
             

	 Title:
	  	 Vice President, Business Development
	  		  	 Title:
	  	
             

  
 2 

 IN WITNESS WHEREOF, the parties have executed this Agreement by their duly authorized
representatives as of the date set forth above. 
  

									
	TSRI:	 		 	SPONSOR:
			
	THE SCRIPPS RESEARCH INSTITUTE	 		 	V1VIDION THERAPEUTICS, INC.
					
	By:	 	              
	 		 	By:	 	 /s/ John Clarke

					
	Title:	 	          
	 		 	Title:	 	 President

  
 3 

 EXHIBIT A-2 

RESEARCH PROGRAM 

  
 4 

 EXHIBIT B-2 

BUDGET 

  
 5 

 AMENDMENT NO. 3 TO RESEARCH FUNDING AND OPTION AGREEMENT 

This is an Amendment 3, dated as of September 13, 2018 (this “Amendment”) to the Research Funding and Option Agreement, dated
September 15, 2014 (the “Funding Agreement), by and between THE SCRIPPS RESEARCH INSTITUTE, a California nonprofit public benefit corporation (“TSRI”), and VIVIDION THERAPEUTICS, INC., a Delaware corporation
(“Sponsor”). 
 RECITALS 
  

	 	A.	 TSRI and Sponsor entered into the Funding Agreement and have been operating under the Funding Agreement since
its effective date. 

  

	 	B.	 TSRI and Sponsor have determined that it is in the best interest of both TSRI and Sponsor to amend the Funding
Agreement as set forth in this Amendment. 

 AGREEMENT 

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, TSRI and Sponsor hereby
agree as follows: 
  

	 	1.	 Amendment of Section 3.1 (b). Paragraph (b) of Section 3.1 of the Funding
Agreement is hereby amended by deleting the second sentence of such paragraph and replacing it with the following: “Any transfer of materials from TSRI to Sponsor or from Sponsor to TSRI under this Section 3.1(b) shall require the
execution of a Material Transfer Agreement.” 

  

	 	2.	 Continuation of Funding Agreement. In all other respects the Funding Agreement remains in full force and
effect as originally executed. 

 IN WITNESS WHEREOF, the parties have executed this Agreement by their duly authorized
representatives as of the date set forth above. 
  

									
	TSRI:	 		 	LICENSEE:
			
	THE SCRIPPS RESEARCH INSTITUTE	 		 	VIVIDION THERAPEUTICS, INC.
					
	Title:	 	/s/ Daniel J. Catron	 		 	Title:	 	 /s/ G. Diego Miralles

	Title:	 	  

17-Sep-2018
	 		 	Title:	 	 Chief Executive Officer

 FOURTH AMENDMENT TO 

RESEARCH FUNDING AND OPTION AGREEMENT 

THIS FOURTH AMENDMENT TO THAT CERTAIN RESEARCH FUNDING AND OPTION AGREEMENT (the “Fourth Amendment”) is entered into as of
January 17, 2020 (the “Amendment Effective Date”) by and between THE SCRIPPS RESEARCH INSTITUTE, a California nonprofit public benefit corporation located at 10550 North Torrey Pines Road, La Jolla, California 92037
(“TSRI”), and Vividion Therapeutics, Inc. (“Sponsor”) located at 5820 Nancy Ridge Drive, San Diego, CA 92121. 

RECITALS 

WHEREAS, TSRI and Sponsor entered into that certain Research Funding and Option Agreement
dated as of September 15, 2014 (the “Agreement”; TSRI 2014-0617); 
 WHEREAS,
TSRI and sponsor have amended the Agreement as dated December 13, 2016 (the First Amendment), February 15, 2017 (the Second Amendment; TSRI 2017-0055), and September 13, 2018 (the Third Amendment); 

WHEREAS, TSRI and Sponsor wish to amend the Agreement in the manner set forth in this
Fourth Amendment. 
 AGREEMENT 

NOW THEREFORE, in consideration of the mutual promises hereinafter set
forth, the parties hereto agree as follows: 
  

	1.	 Section 1.2 is hereby deleted in its entirety and replaced by: 

1.2 Agreement Number. The original Agreement has been assigned TSRI number 2014-0617, the Second Amendment has been assigned TSRI number
2017-0055, and the Fourth Amendment has been assigned TSRI number 2020-0015. 
  

	2.	 Term (section 7.2). The date “February 14, 2020” will be deleted and replaced with
February 14, 2022. 

  

	3.	 The Parties agree that Sponsor shall have an option to extend the Term for an additional one (1) year.

  

	4.	 Exhibit A. The Agreement is amended to include the attached Exhibit
A-3, which updates the progress on the original aims. Exhibit A-3 is incorporated into and made part of the Agreement. References to Exhibit A in the
Agreement are amended to also refer to Exhibit A-3. 

  

	5.	 Exhibit B. The Agreement is amended to include the attached Exhibit B-3, which lists the applicable cost information being added to the Agreement. Exhibit B-3 is incorporated into and made part of the Agreement. References to
Exhibit B in the Agreement are amended to also refer to Exhibit B-3. 

  
 1 

	6.	 Payments. The following payments are added to section 2.4(a): 

 

			
	 12th payment: $[***]
	  	Due: [***]
	 13th payment: $[***]
	  	Due: [***]
	 14th payment: $[***]
	  	Due: [***]
	 15th payment: $[***]
	  	Due: [***]

  

	7.	 General Provisions. The Agreement is amended to add the following clause: 

9.13 Export Controls. It is TSRI’s policy to remain fully in compliance at all times with all U.S. export control regulations,
including but not limited to the Export Administration Regulations; International Traffic in Arms Regulations; and embargo sanctions under the Office of Foreign Assets Control (OFAC). All activities and/or transactions contemplated or hereby agreed
to within this Agreement shall be strictly predicated on full compliance with all U.S. and international export control regulations including but not limited to restricted party prohibitions; export license requirements. In the event that Sponsor
will be providing export controlled material to TSRI, Sponsor must first notify TSRI of its intention to provide this material in advance of shipment. Further, diversion of any kind of any item provided to Sponsor contrary to U.S. laws is strictly
prohibited. In the event that such diversion occurs, TSRI shall not be held liable for any consequential liability, penalties, or enforcement actions undertaken by a U.S. Government agency or any other party in relation to such action. 

 

	8.	 Full Force and Effect. Except as specifically amended by this Fourth Amendment, the terms and conditions
of the Agreement shall remain in full force and effect. 

  

	9.	 Counterparts. This Fourth Amendment may be executed in two or more counterparts, each of which shall be
deemed an original, but all of which together shall constitute one and the same instrument. 

 The Agreement, First Amendment, Second
Amendment, Third Amendment, and this Fourth Amendment (hereinafter collectively the “Agreement”) constitute the entire understanding of Sponsor and TSRI with respect to the subject matter hereof and supersede any prior understanding, oral
or written, between the parties with respect hereto. 
 [SIGNATURES BEGIN ON THE FOLLOWING PAGE] 

  
 2 

 IN WITNESS WHEREOF, the
parties have executed this Fourth Amendment on the day and year first written above. 
  

									
	THE SCRIPPS RESEARCH INSTITUTE	 		 	“SPONSOR”
					
	By:	 	 /s/ Nikki Alvarez
	 		 	By:	 	 /s/ Jean Bemis

					
	Name:	 	 Nikki Alvarez
	 		 	Name:	 	 Jean Bemis

					
	Title:	 	 Director, Alliances
	 		 	Title:	 	 Head of Alliance Management

  
 3 

 EXHIBIT A-3: RESEARCH PROGRAM 

  
 4 

 EXHIBIT B-3: BUDGET 

  
 5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00329-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00329-of-00352.parquet"}]]